ReWalk Robotics (LFWD) 10-Q 10 Nov 20 2020 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2020	Nov. 10, 2020
Document and Entity Information [Abstract]
Entity Registrant Name	ReWalk Robotics Ltd.
Entity Central Index Key	0001607962
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Type	10-Q
Document Period End Date	Sep. 30, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q3
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Common Stock, Shares Outstanding		19,177,201
Entity Current Reporting Status	Yes
Entity Shell Company	false
Entity File Number	001-36612
Entity Interactive Data Current	Yes
Entity Incorporation State Country Code	L3

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands		Sep. 30, 2020	Dec. 31, 2019
CURRENT ASSETS
Cash and cash equivalents		$ 18,050	$ 16,253
Trade receivable, net		715	794
Prepaid expenses and other current assets		833	903
Inventories		3,707	3,123
Total current assets		23,305	21,073
LONG-TERM ASSETS
Restricted cash and other long-term assets		1,034	1,061
Operating lease right-of-use assets		1,421	1,737
Property and equipment, net	[1]	474	501
Total long-term assets		2,929	3,299
Total assets		26,234	24,372
CURRENT LIABILITIES
Current maturities of long-term loans		3,280	5,438
Current maturities of operating leases		622	637
Trade payables		2,107	2,698
Employees and payroll accruals		687	670
Deferred revenues		445	323
Other current liabilities		504	402
Total current liabilities		7,645	10,168
LONG-TERM LIABILITIES
Long-term loan, net of current maturities		154	1,527
Deferred revenues		626	521
Non-current operating leases		985	1,315
Other long-term liabilities		35	61
Total long-term liabilities		1,800	3,424
Total liabilities		9,445	13,592
COMMITMENTS AND CONTINGENT LIABILITIES
Shareholders' equity:
Ordinary share of NIS 0.25 par value-Authorized: 60,000,000 shares at September 30, 2020 and December 31, 2019; Issued and outstanding: 19,158,963 and 7,319,560 shares at September 30, 2020 and December 31, 2019, respectively		1,352	504
Additional paid-in capital		193,937	178,745
Accumulated deficit		(178,500)	(168,469)
Total shareholders' equity		16,789	10,780
Total liabilities and shareholders' equity		$ 26,234	$ 24,372
[1]	Long-lived assets are comprised of property and equipment, net.

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - ₪ / shares	Sep. 30, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Ordinary shares, par value (in NIS per share)	₪ 0.25	₪ 0.25
Ordinary shares, authorized	60,000,000	60,000,000
Ordinary shares, issued	19,158,963	7,319,560
Ordinary shares, outstanding	19,158,963	7,319,560

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Income Statement [Abstract]
Revenues	$ 747	$ 1,234	$ 3,175	$ 3,692
Cost of revenues	355	585	1,388	1,682
Gross profit	392	649	1,787	2,010
Operating expenses:
Research and development, net	756	1,018	2,695	4,292
Sales and marketing	1,507	1,453	4,541	4,571
General and administrative	1,198	1,209	3,774	3,988
Total operating expenses	3,461	3,680	11,010	12,851
Operating loss	(3,069)	(3,031)	(9,223)	(10,841)
Financial expenses, net	242	360	723	1,131
Loss before income taxes	(3,311)	(3,391)	(9,946)	(11,972)
Taxes on income (tax benefit)	25	(2)	85	4
Net loss	$ (3,336)	$ (3,389)	$ (10,031)	$ (11,976)
Net loss per ordinary share, basic and diluted	$ (0.18)	$ (0.46)	$ (0.71)	$ (2.27)
Weighted average number of shares used in computing net loss per ordinary share, basic and diluted	18,881,694	7,290,791	14,132,375	5,284,451

CONDENSED STATEMENTS OF CHANGES

CONDENSED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (Unaudited) - USD ($) $ in Thousands		Ordinary Share		Additional Paid-in Capital	Accumulated deficit	Total
Balance at Dec. 31, 2018		$ 193		$ 154,670	$ (152,918)	$ 1,945
Balance, shares at Dec. 31, 2018		2,813,087
Share-based compensation to employees and non-employees				869		869
Issuance of ordinary shares upon exercise of options to purchase ordinary shares and RSUs by employees and non-employees		$ 1				1
Issuance of ordinary shares upon exercise of options to purchase ordinary shares and RSUs by employees and non-employees, shares		27,985
Issuance of ordinary shares in a "best efforts" offering, net of issuance expenses in the amount of $686	[1]	$ 52		3,632		3,684
Issuance of ordinary shares in a "best efforts" offering, net of issuance expenses in the amount of $686, shares	[1]	760,000
Issuance of ordinary shares in a "best effort" offering, net of issuance expenses in the amount of $1,056	[1]
Exercise of pre-funded warrants and warrants	[1],[2]	$ 40		1,461		1,501
Exercise of pre-funded warrants and warrants, shares	[2]	584,087
Issuance of ordinary shares in a "Registered Direct" offerings, net of issuance expenses in the amount of $1,125	[1]	$ 115		8,010		8,125
Issuance of ordinary shares in a "Registered Direct" offerings, net of issuance expenses in the amount of $1,125, shares	[1]	1,650,248
Issuance of ordinary shares in a "Warrant exercise" agreement, net of issuance expenses in the amount of $1,019	[1]	$ 102		9,864		9,966
Issuance of ordinary shares in a "Warrant exercise" agreement, net of issuance expenses in the amount of $1,019, shares	[1]	1,464,665
Net loss					(11,976)	(11,976)
Balance at Sep. 30, 2019		$ 503		178,506	(164,894)	14,115
Balance, shares at Sep. 30, 2019		7,300,072
Balance at Jun. 30, 2019		$ 503		178,270	(161,505)	17,268
Balance, shares at Jun. 30, 2019		7,289,110
Share-based compensation to employees and non-employees				236		236
Issuance of ordinary shares upon exercise of options to purchase ordinary shares and RSUs by employees and non-employees			[3]
Issuance of ordinary shares upon exercise of options to purchase ordinary shares and RSUs by employees and non-employees, shares		10,962
Net loss					(3,389)	(3,389)
Balance at Sep. 30, 2019		$ 503		178,506	(164,894)	14,115
Balance, shares at Sep. 30, 2019		7,300,072
Balance at Dec. 31, 2019		$ 504		178,745	(168,469)	10,780
Balance, shares at Dec. 31, 2019		7,319,560
Share-based compensation to employees and non-employees				544		544
Issuance of ordinary shares upon exercise of options to purchase ordinary shares and RSUs by employees and non-employees		$ 2		(2)
Issuance of ordinary shares upon exercise of options to purchase ordinary shares and RSUs by employees and non-employees, shares		44,625
Issuance of ordinary shares in a "best effort" offering, net of issuance expenses in the amount of $1,056	[1]	$ 290		3,720		4,010
Issuance of ordinary shares in a "best effort" offering, net of issuance expenses in the amount of $1,056, shares	[1]	4,053,172
Exercise of pre-funded warrants and warrants	[1],[2]	$ 199		3,306		3,505
Exercise of pre-funded warrants and warrants, shares	[1],[2]	2,803,328
Issuance of ordinary shares in a "registered direct" offering, net of issuance expenses in the amount of $ 1,019	[1]	$ 357		7,624		7,981
Issuance of ordinary shares in a "registered direct" offering, net of issuance expenses in the amount of $ 1,019, shares	[1]	4,938,278
Issuance of ordinary shares in a "Warrant exercise" agreement, net of issuance expenses in the amount of $1,019	[1]
Net loss					(10,031)	(10,031)
Balance at Sep. 30, 2020		$ 1,352		193,937	(178,500)	16,789
Balance, shares at Sep. 30, 2020		19,158,963
Balance at Jun. 30, 2020		$ 993		186,070	(175,164)	11,899
Balance, shares at Jun. 30, 2020		14,190,685
Share-based compensation to employees and non-employees				232		232
Issuance of ordinary shares upon exercise of options to purchase ordinary shares and RSUs by employees and non-employees		$ 2		(2)
Issuance of ordinary shares upon exercise of options to purchase ordinary shares and RSUs by employees and non-employees, shares		20,000
Issuance of ordinary shares in a "registered direct" offering, net of issuance expenses in the amount of $ 1,019	[1]	$ 357		7,624		7,981
Issuance of ordinary shares in a "registered direct" offering, net of issuance expenses in the amount of $ 1,019, shares	[1]	4,938,278
Exercise of warrants	[1],[2]			13		13
Exercise of warrants, shaes	[1],[2]	10,000
Net loss					(3,336)	(3,336)
Balance at Sep. 30, 2020		$ 1,352		$ 193,937	$ (178,500)	$ 16,789
Balance, shares at Sep. 30, 2020		19,158,963
[1]	See Note 8f to the condensed consolidated financial statements.
[2]	See Note 8d to the condensed consolidated financial statements.
[3]	Represents an amount lower than $1.

CONDENSED STATEMENTS OF CHANG_2

CONDENSED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (Unaudited) (Parenthetical) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2020	Sep. 30, 2019
Best Efforts [Member]
Issuance expenses, amount		$ 1,056	$ 686
Registered Direct [Member]
Issuance expenses, amount	$ 1,019	$ 1,019	1,125
Warrant Exercise [Member]
Issuance expenses, amount			$ 1,019

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands		9 Months Ended
		Sep. 30, 2020	Sep. 30, 2019
Cash flows used in operating activities:
Net loss		$ (10,031)	$ (11,976)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation		215	242
Share-based compensation to employees and non-employees		544	869
Deferred taxes		(68)	(67)
Financial expenses related to long-term loans		59
Changes in assets and liabilities:
Trade receivables, net		79	186
Prepaid expenses, operating lease right-of-use assets and other assets		33	(397)
Inventories		(634)	(828)
Trade payables		(633)	625
Employees and payroll accruals		17	(56)
Deferred revenues and advances from customers		227	180
Operating lease liabilities and other liabilities		61	(3)
Net cash used in operating activities		(10,131)	(11,225)
Cash flows used in investing activities:
Purchase of property and equipment		(73)	(8)
Net cash used in investing activities		(73)	(8)
Cash flows from financing activities:
Repayment of long-term loan		(3,982)	(1,261)
Proceeds from issuance of long-term debt		392
Issuance of ordinary shares in a "best efforts" offering, net of issuance expenses in the amount of $ 686	[1]		3,684
Issuance of ordinary shares in a "registered direct" offerings, net of issuance expenses in the amount of $1,035	[1]		8,215
Issuance of ordinary shares in a "warrant exercise" agreement, net of issuance expenses in the amount of $ 1,019	[1]		9,966
Issuance of ordinary shares in a "best efforts" offerings, net of issuance expenses paid in the amount of $ 1,056	[1]	4,010
Issuance of ordinary shares in a "registered direct" offerings, net of issuance expenses in the amount of $977	[1]	8,023
Exercise of pre-funded warrants and warrants	[1],[2]	3,505	1,429
Net cash provided by financing activities		11,948	22,033
Increase in cash, cash equivalents, and restricted cash		1,744	10,800
Cash, cash equivalents, and restricted cash at beginning of period		16,992	10,347
Cash, cash equivalents, and restricted cash at end of period		18,736	21,147
Supplemental disclosures of non-cash flow information
"Registered direct" offerings issuance cost not yet paid	[1]	42
Classification of other current assets to property and equipment, net		65	90
Classification of inventory to property and equipment, net		50	88
Cashless exercise of pre-funded warrants	[1],[2]		72
Initial recognition of operating lease right-of-use assets			2,099
Initial recognition of operating lease liabilities			(2,249)
Supplemental cash flow information:
Cash and cash equivalents		18,050	20,410
Restricted cash included in other long-term assets		686	737
Total Cash, cash equivalents, and restricted cash		$ 18,736	$ 21,147
[1]	See Note 8f to the condensed consolidated financial statements.
[2]	See Note 8d to the condensed consolidated financial statements.

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (Parenthetical) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Best Efforts [Member]
Issuance expenses paid	$ 1,056
Best Efforts One [Member]
Issuance expenses paid		$ 686
Registered Direct [Member]
Issuance expenses paid	$ 977	1,035
Warrant Exercise [Member]
Issuance expenses paid		$ 1,019

GENERAL

GENERAL	9 Months Ended
	Sep. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
GENERAL	NOTE 1:- GENERAL a. ReWalk Robotics Ltd. (“RRL”, and together with its subsidiaries, the “Company”) was incorporated under the laws of the State of Israel on June 20, 2001 and commenced operations on the same date. b. RRL has two wholly-owned subsidiaries: (i) ReWalk Robotics Inc. (“RRI”) incorporated under the laws of Delaware on February 15, 2012 and (ii) ReWalk Robotics GMBH. (“RRG”) incorporated under the laws of Germany on January 14, 2013. c. The Company is designing, developing and commercializing robotic exoskeletons that allow individuals with mobility impairments or other medical conditions the ability to stand and walk once again. The Company has developed and is continuing to commercialize the ReWalk, an exoskeleton designed for individuals with paraplegia that uses its patented tilt-sensor technology and an on-board computer and motion sensors to drive motorized legs that power movement. The ReWalk system consists of a light wearable brace support suit which integrates motors at the joints, rechargeable batteries, an array of sensors and a computer-based control system to power knee and hip movement. There are currently two types of ReWalk products: ReWalk Personal and ReWalk Rehabilitation. ReWalk Personal is designed for everyday use by individuals at home and in their communities and is custom-fitted for each user. ReWalk Rehabilitation is designed for the clinical rehabilitation environment where it provides individuals access to valuable exercise and therapy. Additionally, the Company developed and, in June 2019, started to commercialize the ReStore following receipt of European Union CE mark and United States Food and Drug Administration (“FDA”). The ReStore is a powered, lightweight soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke. The Company markets and sells its products directly to institutions and individuals in Germany and the United States and through third-party distributors in other markets. In its direct markets, the Company has established relationships with rehabilitation centers and the spinal cord injury community, and in its indirect markets, the Company’s distributors maintain these relationships. RRI markets and sells products mainly in the United States. RRG sell the Company’s products mainly in Germany and Europe. The company added two new product lines through distribution agreements and started commercializing them during the third quarter. d. The worldwide spread of COVID-19 has resulted in a global economic slowdown and is expected to continue to disrupt general business operations until the disease is contained. This has had a negative impact on the Company's sales and results of operations during 2020, and the Company expects that it will continue to negatively affect its sales and results of operations but the Company is currently unable to predict the scale and duration of that impact. As of the date of issuance of these financial statements, the Company is not aware of any specific event or circumstance that would require an update of its accounting estimates or judgments or revision of the carrying value of its assets or liabilities. This determination may change as new events occur and additional information is obtained. Actual results could differ from our estimates and judgments, and any such differences may be material to our financial statements. e. The Company has an accumulated deficit in the total amount of approximately $179 million as of September 30, 2020 and negative cash flow from operations of $10 million, and further losses are anticipated in the development of its business. Those factors raise substantial doubt about the Company’s ability to continue as a going concern. The ability to continue as a going concern is dependent upon the Company obtaining the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they become due. The Company intends to finance operating costs over the next twelve months with existing cash on hand, continued close examination of its operating spend and potential reduction in specific areas, and future issuances of equity and debt securities, or through a combination of the foregoing. However, the Company will need to seek additional sources of financing if the Company requires more funds than anticipated during the next 12 months or in later periods. The accompanying condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and liabilities and commitments in the normal course of business. The condensed consolidated financial statements for the three and nine months ended September 30, 2020 do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from uncertainty related to the Company’s ability to continue as a going concern.

UNAUDITED INTERIM CONDENSED CON

UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS	9 Months Ended
	Sep. 30, 2020
Unaudited Interim Condensed Consolidated Financial Statements [Abstract]
UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS	NOTE 2:- UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles and standards of the Public Company Accounting Oversight Board for interim financial information. Accordingly, they do not include all the information and footnotes required by generally accepted accounting principles in the United States for complete financial statements. In the opinion of management, the accompanying financial statements include all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation of the Company’s (i) consolidated financial position as of September 30, 2020, (ii) consolidated results of operations for the three and nine months ended September 30, 2020, (iii) consolidated statements of changes in shareholders’ equity as of September 30, 2020 and (iv) consolidated cash flows for the nine months ended September 30, 2020. The results for the three and nine months periods ended September 30, 2020, as applicable, are not necessarily indicative of the results that may be expected for the year ending December 31, 2020.

SIGNIFICANT ACCOUNTING POLICIES

SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
SIGNIFICANT ACCOUNTING POLICIES	NOTE 3:- SIGNIFICANT ACCOUNTING POLICIES a. Revenue Recognition The Company generates revenues from sales of products. The Company sells its products directly to end customers and through distributors. The Company sells its products to private individuals (who finance the purchases by themselves, through fundraising or reimbursement coverage from insurance companies), rehabilitation facilities and distributors. Disaggregation of Revenues (in thousands) Three Months Ended Nine Months Ended 2020 2019 2020 2019 Units placed $ 522 $ 1,104 $ 2,583 $ 3,350 Spare parts and warranties 225 130 592 342 Total Revenues $ 747 $ 1,234 $ 3,175 $ 3,692 Units placed The Company currently offer five products: (1) ReWalk Personal, (2) ReWalk Rehabilitation, (3) ReStore, (4) MyoCycle and (5) MediTouch. ReWalk Personal and ReWalk Rehabilitation are units for spinal cord injuries (“SCI Products”). SCI Products are currently designed for everyday use by paraplegic individuals at home and in their communities, and are custom fitted for each user, as well as for use by paraplegia patients in the clinical rehabilitation environment, where they provide individuals access to valuable exercise and therapy. ReStore is a powered, lightweight soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke in the clinical rehabilitation environment. MyoCycle which uses Functional Electrical Stimulation (“FES”) technology and MediTouch tutor movement biofeedback devices (“Distributed Products”). The Company markets the Distributed Products in the United States for use at home or in clinic. Units placed includes revenue from sales of SCI Products, ReStore and Distributed Products. For units placed, the Company recognizes revenues when it transfers control and title has passed to the customer. Each unit placed is considered an independent, unbundled performance obligation. The Company also offers a rent-to-purchase model in which the Company recognizes revenue ratably according to the agreed rental monthly fee. Spare parts and warranties Spare parts are sold to private individuals, rehabilitation facilities and distributors. Revenue is recognized when the Company satisfies a performance obligation by transferring control over promised goods or services to the customer. Each part sold is considered an independent, unbundled performance obligation. Warranties are classified as either assurance type or service type warranty. A warranty is considered an assurance type warranty if it provides the consumer with assurance that the product will function as intended for a limited period of time. In the beginning of 2018, the Company updated its service policy for SCI Products to include a five- year warranty compared to a period of two years that were included in the past for parts and services. The first two years are considered as assurance type warranty and the additional period is considered an extended service arrangement, which is a service type warranty. An assurance type warranty is not accounted for as separate performance obligations under the revenue model. A service type warranty is either sold with a unit or separately for units for which the warranty has expired. Revenue is then recognized ratably over the life of the warranty. The ReStore device is offered with a two-year warranty which is considered as assurance type warranty. The Distributed Products are offered with assurance type warranty ranging between one year to ten years depending on the specific product and part. Contract balances September 30, December 31, 2020 2019 Trade receivable, net (1) $ 715 $ 794 Deferred revenues (1) (2) $ 1,071 $ 844 (1) Balance presented net of unrecognized revenues that were not yet collected. (2) $345 thousand of December 31, 2019 deferred revenues balance were recognized as revenues during the nine months ended September 30, 2020. Deferred revenue is comprised mainly of unearned revenue related to service type warranty but also includes other offerings for which the Company has been paid in advance and earns revenue when the Company transfers control of the product or service. The Company’s unfilled performance obligations as of September 30, 2020 and the estimated revenue expected to be recognized in the future related to the service type warranty amounts to $1,088 thousand, which is fulfilled over one to five years. b. New Accounting Pronouncements Recent Accounting Pronouncements Not Yet Adopted In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments and subsequent amendments to the initial guidance under ASU 2018-19, ASU 2019-04 and ASU 2019-05, which amends the current approach to estimate credit losses on certain financial assets, including trade and other receivables. Generally, this amendment requires entities to establish a valuation allowance for the expected lifetime losses of these certain financial assets. Upon the initial recognition of such assets, which will be based on, among other things, historical information, current conditions, and reasonable supportable forecasts. Subsequent changes in the valuation allowance are recorded in current earnings and reversal of previous losses are permitted. Currently, U.S. GAAP requires entities to write down credit losses only when losses are probable and loss reversals are not permitted. Originally, ASU 2016-13 was effective for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2019, with early adoption permitted. An entity should apply the standard by recording a cumulative effect adjustment to retained earnings upon adoption. In November 2019, FASB issued ASU No. 2019-10, Financial Instruments – Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842). This ASU defers the effective date of ASU 2016-13 for public companies that are considered smaller reporting companies as defined by the SEC to fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The Company is planning to adopt this standard in the first quarter of fiscal 2023. The adoption of this standard is not expected to result in a material impact to the Company’s financial statements. In August 2020, the FASB issued ASU 2020-06, Accounting for Convertible Instruments and Contracts in an Entity's Own Equity, which simplifies the guidance on the issuer’s accounting for convertible debt instruments by removing the separation models for (1) convertible debt with a cash conversion feature and (2) convertible instruments with a beneficial conversion feature. As a result, entities will not separately present in equity an embedded conversion feature in such debt. Instead, they will account for a convertible debt instrument wholly as debt, unless certain other conditions are met. The elimination of these models will reduce reported interest expense and increase reported net income for entities that have issued a convertible instrument that was within the scope of those models before the adoption of ASU 2020-06. ASU 2020-06 also requires that the effect of potential share settlement be included in the diluted EPS calculation when an instrument may be settled in cash or share. This amendment removes current guidance that allows an entity to rebut this presumption if it has a history or policy of cash settlement. Furthermore, ASU 2020-06 requires the application of the if-converted method for calculating diluted earnings per share, the treasury stock method will be no longer available. In addition, ASU 2020-06 clarifies that an average market price should be used to calculate the diluted EPS denominator in cases in which the exercise prices may change on the basis of an entity’s share price or changes in the entity’s share price may affect the number of shares that may be used to settle a financial instrument and that an entity should use the weighted-average share count from each quarter when calculating the year-to-date weighted-average share. The provisions of ASU 2020-06 are applicable for fiscal years beginning after December 15, 2021, with early adoption permitted no earlier than fiscal years beginning after December 15, 2020. The Company is currently evaluating the impact of ASU 2020-06 on its consolidated financial statements. c. Concentrations of Credit Risks: Concentration of credit risk with respect to trade receivable is primarily limited to a customer to which the Company makes substantial sales. September 30, December 31, 2020 2019 Customer A 15 % * ) Customer B 13 % * ) Customer C 13 % * ) Customer D 13 % * ) Customer E 12 % * ) Customer F 11 % 12 % Customer G * ) 14 % Customer H * ) 13 % Customer I * ) 13 % Customer J * ) 12 % Customer K * ) 12 % Customer L * ) 12 % *) Less than 10% The Company’s trade receivables are geographically diversified and derived primarily from sales to customers in various countries, mainly in the United States and Europe. Concentration of credit risk with respect to trade receivables is limited by credit limits, ongoing credit evaluation and account monitoring procedures. The Company performs ongoing credit evaluations of its distributors based upon a specific review of all significant outstanding invoices. The Company writes off receivables when they are deemed uncollectible and having exhausted all collection efforts. As of September 30, 2020 and December 31, 2019, trade receivables are presented net of allowance for doubtful accounts in the amount of $31 thousand and $31 thousand, respectively, and net of sales return reserve $0 as of September 30, 2020 and $86 thousand as of December 31, 2019. d. Warranty provision The Company provided a two-year standard warranty for its products. In the beginning of 2018, we updated our service policy for new devices sold to include five-year warranties. The Company determined that the first two years of warranty is an assurance-type warranty and records a provision for the estimated cost to repair or replace products under warranty at the time of sale. Factors that affect the Company’s warranty reserve include the number of units sold, historical and anticipated rates of warranty repairs and the cost per repair. US Dollars in Balance at December 31, 2019 $ 227 Provision 60 Usage (133 ) Balance at September 30, 2020 $ 154

INVENTORIES

INVENTORIES	9 Months Ended
	Sep. 30, 2020
Inventory Disclosure [Abstract]
INVENTORIES	NOTE 4:- INVENTORIES The components of inventories are as follows (in thousands): September 30, December 31, 2020 2019 Finished products $ 2,954 $ 2,394 Raw materials 753 729 $ 3,707 $ 3,123

COMMITMENTS AND CONTINGENT LIAB

COMMITMENTS AND CONTINGENT LIABILITIES	9 Months Ended
	Sep. 30, 2020
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENT LIABILITIES	NOTE 5:- COMMITMENTS AND CONTINGENT LIABILITIES a. Purchase commitments: The Company has contractual obligations to purchase goods from its contract manufacturer as well as raw materials from different vendors. Purchase obligations do not include contracts that may be canceled without penalty. As of September 30, 2020, non-cancelable outstanding obligations to the Company’s contract manufacturer and raw material vendors amounted to approximately $0.9 million. b. Operating lease commitment: (i) The Company operates from leased facilities in Israel, the United States and Germany. These leases expire between 2020 and 2023. A portion of our facilities leases is generally subject to annual changes in the Consumer Price Index (CPI). The changes to the CPI are treated as variable lease payments and recognized in the period in which the obligation for those payments was incurred. (ii) RRL and RRG lease cars for their employees under cancelable operating lease agreements expiring at various dates in between 2020 and 2023. A subset of our cars leases is considered variable. The variable lease payments for such cars leases are based on actual mileage incurred at the stated contractual rate. RRL and RRG have an option to be released from these agreements, which may result in penalties in a maximum amount of approximately $23 thousand as of September 30, 2020. The Company’s future lease payments for its facilities and cars, which are presented as current maturities of operating leases and non-current operating leases liabilities on the Company’s condensed consolidated balance sheets as of September 30, 2020 are as follows (in thousands): 2020 $ 167 2021 668 2022 637 2023 461 Total lease payments 1,933 Less: imputed interest (326 ) Present value of future lease payments 1,607 Less: current maturities of operating leases (622 ) Non-current operating leases $ 985 Weighted-average remaining lease term (in years) 2.93 Weighted-average discount rate 12.6 % Lease expense under the Company’s operating leases were $178 thousand and $185 thousand for the three months ended September 30, 2020 and 2019, respectively. For the nine months ended September 30, 2020 and 2019 the lease expense were $553 thousand and $560 thousand, respectively. c. Royalties: The Company’s research and development efforts are financed, in part, through funding from the IIA and BIRD. Since the Company’s inception through September 30, 2020, the Company received funding from the IIA and BIRD in the total amount of $1.97 million and $500 thousand, respectively. Out of the $1.97 million in funding from the IIA, a total amount of $1.57 million were royalty bearing grants (as of September 30, 2020, the Company paid royalties to the IIA in the total amount of $92 thousand), while a total amount of $400 thousand was received in consideration of 209 convertible preferred A shares, which converted after the Company’s initial public offering in September 2014 into ordinary shares in a conversion ratio of 1 to 1. The Company is obligated to pay royalties to the IIA, amounting to 3%of the sales of the products and other related revenues generated from such projects, up to 100% of the grants received. The royalty payment obligations also bear interest at the LIBOR rate. The obligation to pay these royalties is contingent on actual sales of the applicable products and in the absence of such sales, no payment is required. Additionally, the License Agreement requires the Company to pay Harvard royalties on net sales, See note 7 below for more information about the Collaboration Agreement and the License Agreement. Royalties expenses in cost of revenue were $2 and $8 thousand for the three months ended September 30, 2020 and 2019, respectively. For the nine months ended September 30, 2020 and 2019, the royalties expenses were $5 thousand and $13 thousand, respectively. As of September 30, 2020, the contingent liability to the IIA amounted to $1.6 million. The Israeli Research and Development Law provides that know-how developed under an approved research and development program may not be transferred to third parties without the approval of the IIA. Such approval is not required for the sale or export of any products resulting from such research or development. The IIA, under special circumstances, may approve the transfer of IIA-funded know-how outside Israel, in the following cases: (a) the grant recipient pays to the IIA a portion of the sale price paid in consideration for such IIA-funded know-how or in consideration for the sale of the grant recipient itself, as the case may be, which portion will not exceed six times the amount of the grants received plus interest (or three times the amount of the grant received plus interest, in the event that the recipient of the know-how has committed to retain the research and development activities of the grant recipient in Israel after the transfer); (b) the grant recipient receives know-how from a third party in exchange for its IIA-funded know-how; (c) such transfer of IIA-funded know-how arises in connection with certain types of cooperation in research and development activities; or (d) if such transfer of know-how arises in connection with a liquidation by reason of insolvency or receivership of the grant recipient. d. Liens: As discussed in Note 6 to the Company’s audited consolidated financial statements in its annual report on Form 10-K for the fiscal year ended December 31, 2019 (the “2019 Form 10-K”), the Company is party to a loan agreement, as amended (the “Loan Agreement”), with Kreos Capital V (Expert Fund) Limited (“Kreos”), pursuant to which Kreos extended a $20 million line of credit to the Company. In connection with the Loan Agreement, the Company granted Kreos a first priority security interest over all of its assets, including intellectual property and equity interests in its subsidiaries, subject to certain permitted security interests The Company’s other long-term assets in the amount of $686 thousand have been pledged to third parties as a security in respect to lease agreements. Such deposit cannot be pledged to others or withdrawn without the consent of such third party. e. Legal Claims: Occasionally the Company is involved in various claims, lawsuits, regulatory examinations, investigations and other legal matters arising, for the most part, in the ordinary course of business. The outcome of litigation and other legal matters is inherently uncertain. In making a determination regarding accruals, using available information, the Company evaluates the likelihood of an unfavorable outcome in legal or regulatory proceedings to which the Company is a party and records a loss contingency when it is probable a liability has been incurred and the amount of the loss can be reasonably estimated. Where the Company determines an unfavorable outcome is not probable or reasonably estimable, the Company does not accrue for any potential litigation loss. These subjective determinations are based on the status of such legal or regulatory proceedings, the merits of the company's defenses and consultation with legal counsel. Actual outcomes of these legal and regulatory proceedings may materially differ from the Company’s current estimates. It is possible that resolution of one or more of the legal matters currently pending or threatened could result in losses material to the Company’s consolidated results of operations, liquidity or financial condition. As previously disclosed, between September 2016 and January 2017, eight putative class actions on behalf of alleged shareholders that purchased or acquired the Company ordinary shares pursuant and/or traceable to its registration statement on Form F-1 (File No. 333-197344) used in connection with the initial public offering, or the Company’s IPO, were commenced in the following courts: (i) the Superior Court of the State of California, County of San Mateo; (ii) the Superior Court of the Commonwealth of Massachusetts, Suffolk County; (iii) the United States District Court for the Northern District of California; and (iv) the United States District Court for the District of Massachusetts. As of March 31, 2020, all complaints have been dismissed, with one dismissal affirmed on appeal. The actions involved or involve claims under various sections of the Securities Act of 1933, or the Securities Act, against the Company, certain of its current and former directors and officers, the underwriters of the Company’s IPO and certain other defendants. The four actions commenced in the Superior Court of the State of California, County of San Mateo were dismissed in January 2017 for lack of personal jurisdiction, and the action commenced in the United States District Court for the Northern District of California was voluntarily dismissed in March 2017. Additionally, the two actions commenced in the Superior Court of the Commonwealth of Massachusetts, Suffolk County, or the Superior Court, were consolidated in December 2017, and voluntarily dismissed with prejudice in November 2018, after the District Court for the District of Massachusetts partially dismissed the related claims in that court and the parties in the Superior Court entered a stipulation of dismissal with prejudice. The action commenced in the United States District Court for the District of Massachusetts (the “District Court”), alleging violations of Sections 11 and 15 of the Securities Act and Sections 10(b) and 20(a) of the Exchange Act, was partially dismissed on August 23, 2018. In particular, the District Court granted the motion to dismiss the claims under Sections 11 and 15 of the Securities Act, finding that the plaintiff failed to plead a false or misleading statement in the IPO registration statement. The District Court did not address the claims under Sections 10(b) and 20(a) of the Exchange Act because, as a result of the dismissal of the claims under the Securities Act, the lead plaintiff lacked standing to pursue those claims. Because the action in the District Court was styled as a class action, the District Court permitted the plaintiff to file a supplemental memorandum concerning standing or a motion to appoint a substitute or supplemental plaintiff. On September 10, 2018, the plaintiff sought leave to amend his complaint to add a new plaintiff that purportedly has standing to pursue Exchange Act claims, and the Company opposed the motion to amend on September 24, 2018. On May 16, 2019, the court denied the plaintiff’s motion to amend and the complaint was dismissed. Thereafter, the plaintiff timely appealed to the United States Court of Appeals for the First Circuit (the “First Circuit”). The appeal was fully briefed in January 2020 and the court held oral arguments on March 2, 2020. On August 25, the First Circuit affirmed the dismissal and the denial of the plaintiff’s motion to amend. The plaintiff’s deadline to file a petition for certiorari for appeal of the case to the Supreme Court of the United States is November 24, 2020. Based on information currently available and the current stage of the litigation, the Company is unable to reasonably estimate a possible loss or range of possible losses, if any, with regard to the remaining lawsuit in the District Court; therefore, no litigation reserve has been recorded in the Company’s condensed consolidated balance sheets as of September 30, 2020.The Company will continue to evaluate information as it becomes known and will record an estimate for losses at the time or times if and when it is probable that a loss will be incurred and the amount of the loss is reasonably estimable.

PAYCHECK PROTECTION PROGRAM LOA

PAYCHECK PROTECTION PROGRAM LOAN	9 Months Ended
	Sep. 30, 2020
Debt Disclosure [Abstract]
PAYCHECK PROTECTION PROGRAM LOAN	NOTE 6:- PAYCHECK PROTECTION PROGRAM LOAN On April 21, 2020, RRI entered into a loan (the “PPP Loan”) with Silicon Valley Bank (the “Lender”) evidencing an unsecured promissory note in the amount of $392 thousand (the “PPP Note”) pursuant to the Paycheck Protection Program (the “PPP”) under the Coronavirus Aid, Relief, and Economic Security (CARES) Act. Subject to the terms of the PPP Note, the PPP Loan bears interest at a fixed rate of 1% per year, with the first six months of interest deferred, and has an initial term of two years. The PPP Loan is unsecured and guaranteed by the Small Business Administration. The PPP Loan may be used for payroll costs, costs related to certain group health care benefits and insurance premiums, rent payments, utility payments, mortgage interest payments and interest payments on any other debt obligation that were incurred before February 15, 2020. PPP loan recipients can apply for and be granted forgiveness for all or a portion of loan granted under the PPP, with such forgiveness to be determined, subject to limitations, based on the use of the loan proceeds for payment of payroll costs and any payments of mortgage interest, rent, and utilities. The terms of any forgiveness may also be subject to further requirements in any regulations and guidelines the Small Business Administration may adopt. On September 29, 2020, the Company submitted an application for loan forgiveness to the Small Business Administration. The PPP Note provides for customary events of default including, among other things, cross-defaults on any other loan with the Lender. The PPP Loan may be accelerated upon the occurrence of an event of default. The follow table presents the scheduled principal payments of the Company's PPP Loan payable as of September 30, 2020, shown if the PPP Loan is not forgiven: Period Amount Remainder of 2020 $ 43 2021 263 2022 88 Total principal payments $ 394 Current portion $ 240 Long-term portion 154 Note payable, net $ 394

RESEARCH COLLABORATION AGREEMEN

RESEARCH COLLABORATION AGREEMENT AND LICENSE AGREEMENT	9 Months Ended
	Sep. 30, 2020
Research and Development [Abstract]
RESEARCH COLLABORATION AGREEMENT AND LICENSE AGREEMENT	NOTE 7:- RESEARCH COLLABORATION AGREEMENT AND LICENSE AGREEMENT On May 16, 2016, the Company entered into a Research Collaboration Agreement and an Exclusive License Agreement with Harvard. The Research Collaboration Agreement was amended on May 1, 2017 and April 1, 2018 (as amended, the “Collaboration Agreement”), and the Exclusive License Agreement was amended on April 1, 2018 (as amended, the “License Agreement”), to extend the term of the Collaboration Agreement by one year to May 16, 2022 and reallocate the Company’s quarterly installment payments to Harvard through such date, and to make certain technical changes. On April 30, 2020, the Company and Harvard amended the Collaboration Agreement, which included certain adjustments to the quarterly installments and extended the term an additional three quarters until February 2023. Under the Collaboration Agreement, Harvard and the Company have agreed to collaborate on research regarding the development of lightweight “soft suit” exoskeleton system technologies for lower limb disabilities, which are intended to treat stroke, multiple sclerosis, mobility limitations for the elderly and other medical applications. The Company has committed to pay in quarterly installments for the funding of this research, subject to a minimum funding commitment under applicable circumstances. Under the Harvard License Agreement, Harvard has granted the Company an exclusive, worldwide royalty-bearing license under certain patents of Harvard relating to lightweight “soft suit” exoskeleton system technologies for lower limb disabilities, a royalty-free license under certain related know-how and the option to obtain a license under certain inventions conceived under the joint research collaboration. The Harvard License Agreement requires the Company to pay Harvard an upfront fee, reimbursements for expenses that Harvard incurred in connection with the licensed patents, royalties on net sales and several milestone payments contingent upon the achievement of certain product development and commercialization milestones. The Harvard License Agreement will continue in full force and effect until the expiration of the last-to-expire valid claim of the licensed patents. As of September 30, 2020, the company achieved the three development milestones. The Company continues to evaluate the likelihood that the other milestones will be achieved on a quarterly basis. The Company’s total payment obligation under the Collaboration Agreement and the License Agreement is $7.2 million on the date the agreement were signed, some of which is subject to a minimum funding commitment under applicable circumstances as indicated above. The Company has recorded expenses in the amount of $175 thousand and $599 thousand which are part of the total payment obligation indicated above, as research and development expenses related to the License Agreement and to the Collaboration Agreement for the three and nine months ended September 30, 2020, respectively. No withholding tax was deducted from the Company’s payments to Harvard in respect of the Collaboration Agreement and the License Agreement since this is not taxable income in Israel in accordance with Section 170 of the Israel Income Tax Ordinance 1961-5721.

SHAREHOLDERS' EQUITY

SHAREHOLDERS' EQUITY	9 Months Ended
	Sep. 30, 2020
Equity [Abstract]
SHAREHOLDERS' EQUITY	NOTE 8:- SHAREHOLDERS’ EQUITY a. Reverse share split: On March 27, 2019, the Company’s shareholders approved (i) a reverse share split within a range of 1:8 to 1:32, to be effective at the ratio and on a date to be determined by the Board of Directors, and (ii) amendments to the Company’s Articles of Association authorizing an increase in the Company’s authorized share capital (and corresponding authorized number of ordinary shares, proportionally adjusting such number for the reverse share split) by up to NIS 17.5 million. Following the shareholder approval, an authorized committee of the Board of Directors of the Company approved a one-for-twenty-five reverse share split of the Company’s ordinary shares, and the Company filed the Third Amended and Restated Articles of Association of the Company with the Registrar of Companies of the State of Israel to effect the reverse share split and to increase the Company’s authorized share capital after the effect of the reverse share split. The reverse share split became effective on April 1, 2019. Additionally, effective at the same time, the total number of ordinary shares the Company is authorized to issue changed from 250,000,000 shares to 60,000,000 shares, the par value per share of the ordinary shares changed to NIS 0.25 and the authorized share capital of the Company changed from NIS 2,500,000 to NIS 15,000,000. All share and per share data included in these condensed consolidated financial statements, for periods before the three months ended June 30, 2019, give retroactive effect to the reverse stock split. Upon the effectiveness of the reverse share split, every twenty-five shares were automatically combined and converted into one ordinary share. Appropriate adjustments were also made to all outstanding derivative securities of the Company, including all outstanding equity awards and warrants. No fractional shares were issued in connection with the reverse share split. Instead, all fractional shares (including shares underlying outstanding equity awards and warrants) were rounded down to the nearest whole number. b. Share option plans: As of September 30, 2020, and December 31, 2019, the Company had reserved 623,408 and 12,409 ordinary shares, respectively, for issuance to the Company’s and its affiliates’ respective employees, directors, officers and consultants pursuant to equity awards granted under the Company’s 2014 Incentive Compensation Plan (the “2014 Plan”). Options to purchase ordinary shares generally vest over four years, with certain options to non-employee directors vesting quarterly over one year. Any option that is forfeited or canceled before expiration becomes available for future grants under the 2014 Plan. The fair value for options granted during the nine months ended September 30, 2019 was estimated at the date of the grant using a Black-Scholes-Merton option pricing model with the following assumptions: Nine Months Ended 2019 Expected volatility 57.5 % Risk-free rate 2.22 % Dividend yield — % Expected term (in years) 6.11 Share price $ 5.37 There were no options granted during the nine months ended September 30, 2020. The fair value of restricted share units (“RSUs”) granted is determined based on the price of the Company’s ordinary shares on the date of grant. A summary of employee and non-employee directors share options activity during the nine months ended September 30, 2020 is as follows: Number Average exercise price Average remaining contractual life (in years) Aggregate intrinsic value (in thousands) Options outstanding at the beginning of the period 74,713 $ 41.6 6.34 $ 135 Granted — — Exercised — — Forfeited (1,713 ) 133.74 Options outstanding at the end of the period 73,000 $ 39.4 5.57 $ — Options exercisable at the end of the period 53,668 $ 46.39 4.74 $ — A summary of employee and non-employee directors RSUs activity during the nine months ended September 30, 2020 is as follows: Number of shares underlying outstanding RSUs Weighted Unvested RSUs at the beginning of the period 62,378 $ 44.61 Granted 1,238,688 0.85 Vested (44,625 ) 8.86 Forfeited (9,126 ) 8.46 Unvested RSUs at the end of the period 1,247,315 $ 2.78 The weighted average grant date fair value of options granted during the nine months ended September 30, 2019 was $2.98. The weighted average grant date fair value of RSUs granted during the nine months ended September 30, 2020 and 2019 were $1.44 and $4.69, respectively. The aggregate intrinsic value in the table above represents the total intrinsic value that would have been received by the option holders had all option holders that hold options with positive intrinsic value exercised their options on the last date of the exercise period. No options were exercised during the nine months ended September 30, 2020 and 2019. As of September 30, 2020, there were $2.0 million of total unrecognized compensation costs related to non-vested share-based compensation arrangements granted under the Company’s 2012 Equity Incentive Plan and its 2014 Plan. This cost is expected to be recognized over a period of approximately 3.22 years. The number of options and RSUs outstanding as of September 30, 2020 is set forth below, with options separated by range of exercise price. Range of exercise price Options and RSUs outstanding as of Weighted average remaining contractual life (years) (1) Options Weighted average remaining contractual life (years) (1) RSUs only 1,247,315 — — — $5.37 12,425 8.49 4,659 8.49 $20.42 - $33.75 36,299 5.51 26,120 4.70 $37.14 - $38.75 10,092 3.21 10,092 3.21 $50 - $52.5 11,228 4.91 9,841 4.67 $182.5 - $524.25 2,956 4.60 2,956 4.60 1,320,315 5.57 53,668 4.74 (1) Calculation of weighted average remaining contractual term does not include the RSUs that were granted, which have an indefinite contractual term. c. Share-based awards to non-employee consultants: As of September 30, 2020, there are no outstanding options or RSUs held by non-employee consultants. d. Warrants to purchase ordinary shares: The following table summarizes information about warrants outstanding and exercisable as of September 30, 2020: Issuance date Warrants Exercise price per warrant Warrants outstanding and exercisable Contractual (number) (number) December 31, 2015 (1) 4,771 $ 7.500 4,771 See footnote (1) November 1, 2016 (2) 97,496 $ 118.750 97,496 November 1, 2021 December 28, 2016 (3) 1,908 $ 7.500 1,908 See footnote (1) November 20, 2018 (4) 126,839 $ 7.500 126,839 November 20, 2023 November 20, 2018 (5) 106,680 $ 9.375 106,680 November 15, 2023 February 25, 2019 (6) 45,600 $ 7.187 45,600 February 21, 2024 April 5, 2019 (7) 408,457 $ 5.140 408,457 October 7, 2024 April 5, 2019 (8) 49,015 $ 6.503 49,015 April 3, 2024 June 5, 2019 and June 6, 2019 (9) 1,464,665 $ 7.500 1,464,665 June 5, 2024 June 5, 2019 (10) 87,880 $ 9.375 87,880 June 5, 2024 June 12, 2019 (11) 416,667 $ 6.000 416,667 December 12, 2024 June 10, 2019 (12) 50,000 $ 7.500 50,000 June 10, 2024 February 10, 2020 (13) 4,343,500 $ 1.250 4,343,500 February 10, 2025 February 10, 2020 (14) 336,000 $ 1.5625 336,000 February 10, 2025 July 6, 2020 (15) 2,469,139 $ 1.76 2,469,139 July 2, 2025 July 6, 2020 (16) 296,297 2.2781 296,297 July 2, 2025 10,304,914 10,304,914 (1) Represents warrants for ordinary shares issuable upon an exercise price of $7.5 per share, which were granted on December 31, 2015 to Kreos Capital V (Expert) Fund Limited, or Kreos, in connection with a loan made by Kreos to us and are currently exercisable (in whole or in part) until the earlier of (i) December 30, 2025 or (ii) immediately prior to the consummation of a merger, consolidation, or reorganization of us with or into, or the sale or license of all or substantially all the assets or shares of us to, any other entity or person, other than a wholly-owned subsidiary of us, excluding any transaction in which our shareholders prior to the transaction will hold more than 50% of the voting and economic rights of the surviving entity after the transaction. None of these warrants had been exercised as of September 30, 2020. (2) Represents warrants issued as part of our follow-on offering in November 2016. At any time, the board of directors may reduce the exercise price of the warrants to any amount and for any period of time it deems appropriate. (3) Represents common warrants that were issued as part of the $8.0 million drawdown under the Loan Agreement which occurred on December 28, 2016. See footnote 1 for exercisability terms. (4) Represents common warrants that were issued as part of our follow-on offering in November 2018. (5) Represents common warrants that were issued to the underwriters as compensation for their role in our follow-on offering in November 2018. (6) Represents warrants that were issued to the exclusive placement agent as compensation for its role in our follow-on offering in February 2019. (7) Represents warrants that were issued to certain institutional purchasers in a private placement in our registered direct offering of ordinary shares in April 2019. (8) Represents warrants that were issued to the placement agent as compensation for its role in our April 2019 registered direct offering. (9) Represents warrants that were issued to certain institutional investors in a warrant exercise agreement on June 5, 2019 and June 6, 2019, respectively. (10) Represents warrants that were issued to the placement agent as compensation for its role in our June 2019 warrant exercise agreement and concurrent private placement of warrants. (11) Represents warrants that were issued to certain institutional purchasers in a private placement in the Company’s registered direct offering of ordinary shares in June 2019. (12) Represents warrants that were issued to the placement agent as compensation for its role in our June 2019 registered direct offering and concurrent private placement of warrants. (13) Represents warrants that were issued to certain institutional purchasers in a private placement in the Company’s best efforts offering of ordinary shares in February 2020. (14) Represents warrants that were issued to the placement agent as compensation for its role in the Company’s February 2020 best efforts offering. (15) Represents warrants that were issued to certain institutional purchasers in a private placement in our registered direct offering of ordinary shares in July 2020. (16) Represents warrants that were issued to the placement agent as compensation for its role in the Company’s July 2020 registered direct offering. e. Share-based compensation expense for employees and non-employees: The Company recognized non-cash share-based compensation expense for both employees and non-employees in the condensed consolidated statements of operations as follows (in thousands): Nine Months Ended 2020 2019 Cost of revenues $ 6 $ 9 Research and development, net 105 161 Sales and marketing 113 140 General and administrative 320 559 Total $ 544 $ 869 f. Equity raise: 1. Follow-on offerings In November 2018, the Company entered into an underwriting agreement with H.C. Wainwright & Co., LLC (“H.C. Wainwright”), in connection with the Company’s follow-on public offering of 496,040 units, each consisting of one ordinary share and one common warrant to purchase one ordinary share with an exercise price of $7.5 per warrant. Each unit was sold to the public at a price of $7.50 per unit. On November 18, 2018, H.C. Wainwright exercised in full its option to purchase 231,964 ordinary shares for $7.25 per share and/or common warrants to purchase up to an additional 231,964 ordinary shares for $0.25 per warrant. Additionally, the Company issued and sold 1,050,372 pre-funded units at a price to the public of $7.25 per unit. Each unit containing one pre-funded warrant with an exercise price of $0.25 per share and one warrant to purchase one ordinary share with an exercise price of $7.50 per warrant. The total gross proceeds received from the November 2018 follow-on public offering, before deducting commissions, discounts and expenses, were $13.1 million (including proceeds from the exercise of 90,691 pre-funded warrants at the closing of the offering). As of December 31, 2018, additional pre-funded warrants to purchase an aggregate 562,466 ordinary shares had been exercised, for additional proceeds of $140,617. During the nine month ended September 30, 2019 additional 288,000 pre-funded warrants and 296,087 warrants to purchase an aggregate 584,087 ordinary shares had been exercised, for additional proceeds of $1.5 million. As compensation for their role in the offering, the Company also issued to the underwriters warrants to purchase up to 106,680 ordinary shares, which became immediately exercisable starting on November 20, 2018 until November 15, 2023 at $9.375 per share. In February 2019, the Company entered into an exclusive placement agent agreement with H.C. Wainwright, on a reasonable best-efforts basis in connection with a public offering of 760,000 ordinary shares at a price of $5.75 per share. The total gross proceeds received from the February 2019 follow-on public offering, before deducting commissions, discounts and expenses, were $4.37 million. The Company also issued to H.C Wainwright and/or its designees warrants to purchase up to 45,600 ordinary shares, which are immediately exercisable starting on February 25, 2019 until February 21, 2024 at $7.1875 per share. In April 2019, the Company entered into securities purchase agreements with certain institutional purchasers whereby the Company issued 816,914 ordinary shares at $5.2025 per ordinary share and warrants to purchase up to 408,457 ordinary shares with an exercise price of $5.14 per share, exercisable from April 5, 2019 until October 7, 2024, in a private placement that took place concurrently with the Company’s registered direct offering of ordinary shares in April 2019. Additionally the Company issued warrants to purchase up to 49,015 ordinary shares, with an exercise price of $6.503125 per share, exercisable from April 5, 2019 until April 3, 2024, to representatives of H.C. Wainwright as compensation for its role as the placement agent in our April 2019 registered direct offering and concurrent private placement of warrants. On June 5, 2019 and June 6, 2019, the Company entered into warrant exercise agreements with certain institutional investors whereby the Company issued warrants to purchase up to 1,464,665 ordinary shares with an exercise price of $7.50 per share, exercisable from June 5, 2019 or June 6, 2019 until June 5, 2024 or June 6, 2024, respectively. Additionally, the Company issued warrants to purchase up to 87,880 ordinary shares, with an exercise price of $9.375 per share, exercisable from June 5, 2019 until June 5, 2024, to certain representatives of H.C. Wainwright as compensation for its role as the placement agent in our June 2019 warrant exercise agreement and concurrent private placement of warrants. On June 12, 2019, the Company entered into a purchase agreement with certain institutional investors for the issuance and sale of 833,334 ordinary shares, par value NIS 0.25 per share at $6.00 per ordinary share and warrants to purchase up to 416,667 ordinary shares with an exercise price of $6.00 per share, exercisable from June 12, 2019 until December 12, 2024, in a private placement that took place concurrently with our registered direct offering of ordinary shares in June 2019. Additionally, the Company issued warrants to purchase up to 50,000 ordinary shares, with an exercise price of $7.50 per share, exercisable from June 12, 2019 until June 10, 2024, to certain representatives of H.C. Wainwright as compensation for its role as the placement agent in our June 2019 registered direct offering and concurrent private placement of warrants. On February 10, 2020, the Company closed a “best efforts” public offering whereby the Company issued an aggregate of 5,600,000 of common units and pre-funded units at a public offering price of $1.25 per common unit and $1.249 per pre-funded unit. As part of the public offering, the Company entered into a securities purchase agreement with certain institutional purchasers. Each common unit consisted of one ordinary share, par value NIS 0.25 per share, and one common warrant to purchase one ordinary share. Each of the 1,546,828 pre-funded unit consisted of one pre-funded warrant to purchase one ordinary share and one common warrant. Additionally, the Company issued warrants to purchase up to 336,000 ordinary shares, with an exercise price of $1.5625 per share, to representatives of H.C. Wainwright as compensation for its role as the placement agent in the Company’s February 2020 offering. During the three months ended March 31, 2020, all pre-funded warrants to purchase ordinary shares were exercised. During the three months ended September 30, 2020, 10,000 warrants to purchase ordinary shares were exercised. As of September 30, 2020, a total of 1,256,500 warrants to purchase ordinary shares were exercised. On July 6, 2020 the Company entered into a purchase agreement with certain institutional investors for the issuance and sale of (i) 4,938,278 ordinary shares, par value NIS 0.25 per share, at a price of $1.8225 per ordinary share and (ii) warrants to purchase up to 2,469,139 ordinary shares with an exercise price of $1.76 per share, exercisable from July 6, 2020 until January 6, 2026. Additionally, the Company issued warrants to purchase up to 296,297 ordinary shares, with an exercise price of $2.2781 per share, exercisable from July 6, 2020 until July 2, 2025, to certain representatives of H.C. Wainwright as compensation for its role as the placement agent in its July 2020 registered direct offering. 3. Investment agreement In May 2018, the Company entered into a fee and release agreement with Canaccord Genuity LLC (“Canaccord Genuity”) requiring the Company to pay to Canaccord Genuity, in connection with a settlement, in addition to certain cash amounts, (i) $125 thousand in ordinary shares of the Company after the closing of the first tranche on May 15, 2018 (the “First Tranche Closing”) of the Timwell transaction and (ii) $225 thousand in ordinary shares of the Company after the closing of the Second Tranche of the Timwell transaction (or such lower amount if the Second Tranche Closing is less than $10.0 million). The price per share used for calculation of the number of ordinary shares issued by the Company to Canaccord Genuity is based on the volume weighted average price of the Company’s ordinary shares as reported on the Nasdaq Capital Market for the five consecutive trading days prior to the date of issuance. The Company is also obligated to pay $100 thousand in cash following the closing of the Third Tranche of $5.0 million (or such lower amount if the Third Tranche Closing is less than $5.0 million). Following the First Tranche Closing, the Company issued 4,715 ordinary shares to Canaccord Genuity. In late March 2020, Timwell notified the Company that it would not invest the second and third tranches under the Investment Agreement. In response, in early April 2020, the Company’s Board of Directors also removed Timwell’s designee, who was appointed pursuant to the Investment Agreement, from the Board of Directors, due to this breach pursuant to the terms of the Investment Agreement. As the Company continues to view China as a market with key opportunities for products designed for stroke patients, the Company continues to evaluate potential relationships with other groups to penetrate the Chinese market.

FINANCIAL EXPENSES, NET

FINANCIAL EXPENSES, NET	9 Months Ended
	Sep. 30, 2020
Other Income and Expenses [Abstract]
FINANCIAL EXPENSES, NET	NOTE 9:- FINANCIAL EXPENSES, NET The components of financial expenses, net were as follows (in thousands): Three Months Ended Nine Months Ended 2020 2019 2020 2019 Foreign currency transactions and other $ (7 ) $ (10 ) $ (99 ) $ (50 ) Financial expenses related to loan agreement with Kreos 243 365 802 1,155 Bank commissions 6 5 20 26 $ 242 $ 360 $ 723 $ 1,131

GEOGRAPHIC INFORMATION AND MAJO

GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA	9 Months Ended
	Sep. 30, 2020
Segment Reporting [Abstract]
GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA	NOTE 10:- GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA Summary information about geographic areas: ASC 280, “Segment Reporting” establishes standards for reporting information about operating segments. Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company manages its business on the basis of one reportable segment, and derives revenues from selling units and services (see Note 1 for a brief description of the Company’s business). The following is a summary of revenues within geographic areas: Three Months Ended Nine Months Ended 2020 2019 2020 2019 Revenues based on customer’s location: Israel $ — $ — $ — $ 2 United States 325 569 1,172 1,492 Europe 413 665 1,990 2,162 Asia-Pacific 2 — 6 36 Latin America 6 — 6 — Africa 1 — 1 — Total revenues $ 747 $ 1,234 $ 3,175 $ 3,692 September 30, December 31, 2020 2019 Long-lived assets by geographic region (*): Israel $ 155 $ 179 United States 263 244 Germany 56 78 $ 474 $ 501 (*) Long-lived assets are comprised of property and equipment, net. Nine Months Ended 2020 2019 Major customer data as a percentage of total revenues: Customer A * ) 13.13 %

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	9 Months Ended
	Sep. 30, 2020
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 11:- SUBSEQUENT EVENTS On November 6, 2020 the Company received confirmation of its PPP Note forgiveness, see note 6 above for further details.

SIGNIFICANT ACCOUNTING POLICI_2

SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
Revenue Recognition	a. Revenue Recognition The Company generates revenues from sales of products. The Company sells its products directly to end customers and through distributors. The Company sells its products to private individuals (who finance the purchases by themselves, through fundraising or reimbursement coverage from insurance companies), rehabilitation facilities and distributors. Disaggregation of Revenues (in thousands) Three Months Ended Nine Months Ended 2020 2019 2020 2019 Units placed $ 522 $ 1,104 $ 2,583 $ 3,350 Spare parts and warranties 225 130 592 342 Total Revenues $ 747 $ 1,234 $ 3,175 $ 3,692 Units placed The Company currently offer five products: (1) ReWalk Personal, (2) ReWalk Rehabilitation, (3) ReStore, (4) MyoCycle and (5) MediTouch. ReWalk Personal and ReWalk Rehabilitation are units for spinal cord injuries (“SCI Products”). SCI Products are currently designed for everyday use by paraplegic individuals at home and in their communities, and are custom fitted for each user, as well as for use by paraplegia patients in the clinical rehabilitation environment, where they provide individuals access to valuable exercise and therapy. ReStore is a powered, lightweight soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke in the clinical rehabilitation environment. MyoCycle which uses Functional Electrical Stimulation (“FES”) technology and MediTouch tutor movement biofeedback devices (“Distributed Products”). The Company markets the Distributed Products in the United States for use at home or in clinic. Units placed includes revenue from sales of SCI Products, ReStore and Distributed Products. For units placed, the Company recognizes revenues when it transfers control and title has passed to the customer. Each unit placed is considered an independent, unbundled performance obligation. The Company also offers a rent-to-purchase model in which the Company recognizes revenue ratably according to the agreed rental monthly fee. Spare parts and warranties Spare parts are sold to private individuals, rehabilitation facilities and distributors. Revenue is recognized when the Company satisfies a performance obligation by transferring control over promised goods or services to the customer. Each part sold is considered an independent, unbundled performance obligation. Warranties are classified as either assurance type or service type warranty. A warranty is considered an assurance type warranty if it provides the consumer with assurance that the product will function as intended for a limited period of time. In the beginning of 2018, the Company updated its service policy for SCI Products to include a five- year warranty compared to a period of two years that were included in the past for parts and services. The first two years are considered as assurance type warranty and the additional period is considered an extended service arrangement, which is a service type warranty. An assurance type warranty is not accounted for as separate performance obligations under the revenue model. A service type warranty is either sold with a unit or separately for units for which the warranty has expired. Revenue is then recognized ratably over the life of the warranty. The ReStore device is offered with a two-year warranty which is considered as assurance type warranty. The Distributed Products are offered with assurance type warranty ranging between one year to ten years depending on the specific product and part. Contract balances September 30, December 31, 2020 2019 Trade receivable, net (1) $ 715 $ 794 Deferred revenues (1) (2) $ 1,071 $ 844 (1) Balance presented net of unrecognized revenues that were not yet collected. (2) $345 thousand of December 31, 2019 deferred revenues balance were recognized as revenues during the nine months ended September 30, 2020. Deferred revenue is comprised mainly of unearned revenue related to service type warranty but also includes other offerings for which the Company has been paid in advance and earns revenue when the Company transfers control of the product or service. The Company’s unfilled performance obligations as of September 30, 2020 and the estimated revenue expected to be recognized in the future related to the service type warranty amounts to $1,088 thousand, which is fulfilled over one to five years.
New Accounting Pronouncements	b. New Accounting Pronouncements Recent Accounting Pronouncements Not Yet Adopted In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments and subsequent amendments to the initial guidance under ASU 2018-19, ASU 2019-04 and ASU 2019-05, which amends the current approach to estimate credit losses on certain financial assets, including trade and other receivables. Generally, this amendment requires entities to establish a valuation allowance for the expected lifetime losses of these certain financial assets. Upon the initial recognition of such assets, which will be based on, among other things, historical information, current conditions, and reasonable supportable forecasts. Subsequent changes in the valuation allowance are recorded in current earnings and reversal of previous losses are permitted. Currently, U.S. GAAP requires entities to write down credit losses only when losses are probable and loss reversals are not permitted. Originally, ASU 2016-13 was effective for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2019, with early adoption permitted. An entity should apply the standard by recording a cumulative effect adjustment to retained earnings upon adoption. In November 2019, FASB issued ASU No. 2019-10, Financial Instruments – Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842). This ASU defers the effective date of ASU 2016-13 for public companies that are considered smaller reporting companies as defined by the SEC to fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The Company is planning to adopt this standard in the first quarter of fiscal 2023. The adoption of this standard is not expected to result in a material impact to the Company’s financial statements. In August 2020, the FASB issued ASU 2020-06, Accounting for Convertible Instruments and Contracts in an Entity's Own Equity, which simplifies the guidance on the issuer’s accounting for convertible debt instruments by removing the separation models for (1) convertible debt with a cash conversion feature and (2) convertible instruments with a beneficial conversion feature. As a result, entities will not separately present in equity an embedded conversion feature in such debt. Instead, they will account for a convertible debt instrument wholly as debt, unless certain other conditions are met. The elimination of these models will reduce reported interest expense and increase reported net income for entities that have issued a convertible instrument that was within the scope of those models before the adoption of ASU 2020-06. ASU 2020-06 also requires that the effect of potential share settlement be included in the diluted EPS calculation when an instrument may be settled in cash or share. This amendment removes current guidance that allows an entity to rebut this presumption if it has a history or policy of cash settlement. Furthermore, ASU 2020-06 requires the application of the if-converted method for calculating diluted earnings per share, the treasury stock method will be no longer available. In addition, ASU 2020-06 clarifies that an average market price should be used to calculate the diluted EPS denominator in cases in which the exercise prices may change on the basis of an entity’s share price or changes in the entity’s share price may affect the number of shares that may be used to settle a financial instrument and that an entity should use the weighted-average share count from each quarter when calculating the year-to-date weighted-average share. The provisions of ASU 2020-06 are applicable for fiscal years beginning after December 15, 2021, with early adoption permitted no earlier than fiscal years beginning after December 15, 2020. The Company is currently evaluating the impact of ASU 2020-06 on its consolidated financial statements.
Concentrations of Credit Risks:	c. Concentrations of Credit Risks: Concentration of credit risk with respect to trade receivable is primarily limited to a customer to which the Company makes substantial sales. September 30, December 31, 2020 2019 Customer A 15 % * ) Customer B 13 % * ) Customer C 13 % * ) Customer D 13 % * ) Customer E 12 % * ) Customer F 11 % 12 % Customer G * ) 14 % Customer H * ) 13 % Customer I * ) 13 % Customer J * ) 12 % Customer K * ) 12 % Customer L * ) 12 % *) Less than 10% The Company’s trade receivables are geographically diversified and derived primarily from sales to customers in various countries, mainly in the United States and Europe. Concentration of credit risk with respect to trade receivables is limited by credit limits, ongoing credit evaluation and account monitoring procedures. The Company performs ongoing credit evaluations of its distributors based upon a specific review of all significant outstanding invoices. The Company writes off receivables when they are deemed uncollectible and having exhausted all collection efforts. As of September 30, 2020 and December 31, 2019, trade receivables are presented net of allowance for doubtful accounts in the amount of $31 thousand and $31 thousand, respectively, and net of sales return reserve $0 as of September 30, 2020 and $86 thousand as of December 31, 2019.
Warranty provision	d. Warranty provision The Company provided a two-year standard warranty for its products. In the beginning of 2018, we updated our service policy for new devices sold to include five-year warranties. The Company determined that the first two years of warranty is an assurance-type warranty and records a provision for the estimated cost to repair or replace products under warranty at the time of sale. Factors that affect the Company’s warranty reserve include the number of units sold, historical and anticipated rates of warranty repairs and the cost per repair. US Dollars in Balance at December 31, 2019 $ 227 Provision 60 Usage (133 ) Balance at September 30, 2020

SIGNIFICANT ACCOUNTING POLICI_3

SIGNIFICANT ACCOUNTING POLICIES (Tables)	9 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
Schedule of disaggregation of revenues	Disaggregation of Revenues (in thousands) Three Months Ended Nine Months Ended 2020 2019 2020 2019 Units placed $ 522 $ 1,104 $ 2,583 $ 3,350 Spare parts and warranties 225 130 592 342 Total Revenues $ 747 $ 1,234 $ 3,175 $ 3,692
Schedule of Contract balances	Contract balances September 30, December 31, 2020 2019 Trade receivable, net (1) $ 715 $ 794 Deferred revenues (1) (2) $ 1,071 $ 844 (1) Balance presented net of unrecognized revenues that were not yet collected. (2) $345 thousand of December 31, 2019 deferred revenues balance were recognized as revenues during the nine months ended September 30, 2020.
Schedule of concentration of credit risk	September 30, December 31, 2020 2019 Customer A 15 % * ) Customer B 13 % * ) Customer C 13 % * ) Customer D 13 % * ) Customer E 12 % * ) Customer F 11 % 12 % Customer G * ) 14 % Customer H * ) 13 % Customer I * ) 13 % Customer J * ) 12 % Customer K * ) 12 % Customer L * ) 12 % *) Less than 10%
Schedule of product warranty liability	US Dollars in Balance at December 31, 2019 $ 227 Provision 60 Usage (133 ) Balance at September 30, 2020

INVENTORIES (Tables)

INVENTORIES (Tables)	9 Months Ended
	Sep. 30, 2020
Inventory Disclosure [Abstract]
Schedule of inventories	The components of inventories are as follows (in thousands): September 30, December 31, 2020 2019 Finished products $ 2,954 $ 2,394 Raw materials 753 729 $ 3,707 $ 3,123

COMMITMENTS AND CONTINGENT LI_2

COMMITMENTS AND CONTINGENT LIABILITIES (Tables)	9 Months Ended
	Sep. 30, 2020
Commitments and Contingencies Disclosure [Abstract]
Schedule of future minimum lease commitments	The Company’s future lease payments for its facilities and cars, which are presented as current maturities of operating leases and non-current operating leases liabilities on the Company’s condensed consolidated balance sheets as of September 30, 2020 are as follows (in thousands): 2020 $ 167 2021 668 2022 637 2023 461 Total lease payments 1,933 Less: imputed interest (326 ) Present value of future lease payments 1,607 Less: current maturities of operating leases (622 ) Non-current operating leases $ 985 Weighted-average remaining lease term (in years) 2.93 Weighted-average discount rate 12.6 %

PAYCHECK PROTECTION PROGRAM L_2

PAYCHECK PROTECTION PROGRAM LOAN (Tables)	9 Months Ended
	Sep. 30, 2020
Debt Disclosure [Abstract]
Scheduled of principal payments of the Company's PPP Loan payable	The follow table presents the scheduled principal payments of the Company's PPP Loan payable as of September 30, 2020, shown if the PPP Loan is not forgiven: Period Amount Remainder of 2020 $ 43 2021 263 2022 88 Total principal payments $ 394 Current portion $ 240 Long-term portion 154 Note payable, net $ 394

SHAREHOLDERS' EQUITY (Tables)

SHAREHOLDERS' EQUITY (Tables)	9 Months Ended
	Sep. 30, 2020
Share-based Payment Arrangement [Abstract]
Schedule of Black-Scholes-Merton option pricing model assumptions	The fair value for options granted during the nine months ended September 30, 2019 was estimated at the date of the grant using a Black-Scholes-Merton option pricing model with the following assumptions: Nine Months Ended 2019 Expected volatility 57.5 % Risk-free rate 2.22 % Dividend yield — % Expected term (in years) 6.11 Share price $ 5.37
Schedule of employee options activity	A summary of employee and non-employee directors share options activity during the nine months ended September 30, 2020 is as follows: Number Average exercise price Average remaining contractual life (in years) Aggregate intrinsic value (in thousands) Options outstanding at the beginning of the period 74,713 $ 41.6 6.34 $ 135 Granted — — Exercised — — Forfeited (1,713 ) 133.74 Options outstanding at the end of the period 73,000 $ 39.4 5.57 $ — Options exercisable at the end of the period 53,668 $ 46.39 4.74 $ —
Schedule of employee RSUs activity	A summary of employee and non-employee directors RSUs activity during the nine months ended September 30, 2020 is as follows: Number of shares underlying outstanding RSUs Weighted Unvested RSUs at the beginning of the period 62,378 $ 44.61 Granted 1,238,688 0.85 Vested (44,625 ) 8.86 Forfeited (9,126 ) 8.46 Unvested RSUs at the end of the period 1,247,315 $ 2.78
Schedule of options and RSUs outstanding	The number of options and RSUs outstanding as of September 30, 2020 is set forth below, with options separated by range of exercise price. Range of exercise price Options and RSUs outstanding as of Weighted average remaining contractual life (years) (1) Options Weighted average remaining contractual life (years) (1) RSUs only 1,247,315 — — — $5.37 12,425 8.49 4,659 8.49 $20.42 - $33.75 36,299 5.51 26,120 4.70 $37.14 - $38.75 10,092 3.21 10,092 3.21 $50 - $52.5 11,228 4.91 9,841 4.67 $182.5 - $524.25 2,956 4.60 2,956 4.60 1,320,315 5.57 53,668 4.74 (1) Calculation of weighted average remaining contractual term does not include the RSUs that were granted, which have an indefinite contractual term.
Schedule of warrants outstanding and exercisable	The following table summarizes information about warrants outstanding and exercisable as of September 30, 2020: Issuance date Warrants Exercise price per warrant Warrants outstanding and exercisable Contractual (number) (number) December 31, 2015 (1) 4,771 $ 7.500 4,771 See footnote (1) November 1, 2016 (2) 97,496 $ 118.750 97,496 November 1, 2021 December 28, 2016 (3) 1,908 $ 7.500 1,908 See footnote (1) November 20, 2018 (4) 126,839 $ 7.500 126,839 November 20, 2023 November 20, 2018 (5) 106,680 $ 9.375 106,680 November 15, 2023 February 25, 2019 (6) 45,600 $ 7.187 45,600 February 21, 2024 April 5, 2019 (7) 408,457 $ 5.140 408,457 October 7, 2024 April 5, 2019 (8) 49,015 $ 6.503 49,015 April 3, 2024 June 5, 2019 and June 6, 2019 (9) 1,464,665 $ 7.500 1,464,665 June 5, 2024 June 5, 2019 (10) 87,880 $ 9.375 87,880 June 5, 2024 June 12, 2019 (11) 416,667 $ 6.000 416,667 December 12, 2024 June 10, 2019 (12) 50,000 $ 7.500 50,000 June 10, 2024 February 10, 2020 (13) 4,343,500 $ 1.250 4,343,500 February 10, 2025 February 10, 2020 (14) 336,000 $ 1.5625 336,000 February 10, 2025 July 6, 2020 (15) 2,469,139 $ 1.76 2,469,139 July 2, 2025 July 6, 2020 (16) 296,297 2.2781 296,297 July 2, 2025 10,304,914 10,304,914 (1) Represents warrants for ordinary shares issuable upon an exercise price of $7.5 per share, which were granted on December 31, 2015 to Kreos Capital V (Expert) Fund Limited, or Kreos, in connection with a loan made by Kreos to us and are currently exercisable (in whole or in part) until the earlier of (i) December 30, 2025 or (ii) immediately prior to the consummation of a merger, consolidation, or reorganization of us with or into, or the sale or license of all or substantially all the assets or shares of us to, any other entity or person, other than a wholly-owned subsidiary of us, excluding any transaction in which our shareholders prior to the transaction will hold more than 50% of the voting and economic rights of the surviving entity after the transaction. None of these warrants had been exercised as of September 30, 2020 (2) Represents warrants issued as part of our follow-on offering in November 2016. At any time, the board of directors may reduce the exercise price of the warrants to any amount and for any period of time it deems appropriate. (3) Represents common warrants that were issued as part of the $8.0 million drawdown under the Loan Agreement which occurred on December 28, 2016. See footnote 1 for exercisability terms. (4) Represents common warrants that were issued as part of our follow-on offering in November 2018. (5) Represents common warrants that were issued to the underwriters as compensation for their role in our follow-on offering in November 2018. (6) Represents warrants that were issued to the exclusive placement agent as compensation for its role in our follow-on offering in February 2019. (7) Represents warrants that were issued to certain institutional purchasers in a private placement in our registered direct offering of ordinary shares in April 2019. (8) Represents warrants that were issued to the placement agent as compensation for its role in our April 2019 registered direct offering. (9) Represents warrants that were issued to certain institutional investors in a warrant exercise agreement on June 5, 2019 and June 6, 2019, respectively. (10) Represents warrants that were issued to the placement agent as compensation for its role in our June 2019 warrant exercise agreement and concurrent private placement of warrants. (11) Represents warrants that were issued to certain institutional purchasers in a private placement in the Company’s registered direct offering of ordinary shares in June 2019. (12) Represents warrants that were issued to the placement agent as compensation for its role in our June 2019 registered direct offering and concurrent private placement of warrants. (13) Represents warrants that were issued to certain institutional purchasers in a private placement in the Company’s best efforts offering of ordinary shares in February 2020. (14) Represents warrants that were issued to the placement agent as compensation for its role in the Company’s February 2020 best efforts offering. (15) Represents warrants that were issued to certain institutional purchasers in a private placement in our registered direct offering of ordinary shares in July 2020. (16) Represents warrants that were issued to the placement agent as compensation for its role in the Company’s July 2020 registered direct offering.
Schedule of non-cash share-based compensation expense	The Company recognized non-cash share-based compensation expense for both employees and non-employees in the condensed consolidated statements of operations as follows (in thousands): Nine Months Ended 2020 2019 Cost of revenues $ 6 $ 9 Research and development, net 105 161 Sales and marketing 113 140 General and administrative 320 559 Total $ 544 $ 869

FINANCIAL EXPENSES, NET (Tables

FINANCIAL EXPENSES, NET (Tables)	9 Months Ended
	Sep. 30, 2020
Other Income and Expenses [Abstract]
Schedule of financial expenses, net	The components of financial expenses, net were as follows (in thousands): Three Months Ended Nine Months Ended 2020 2019 2020 2019 Foreign currency transactions and other $ (7 ) $ (10 ) $ (99 ) $ (50 ) Financial expenses related to loan agreement with Kreos 243 365 802 1,155 Bank commissions 6 5 20 26 $ 242 $ 360 $ 723 $ 1,131

GEOGRAPHIC INFORMATION AND MA_2

GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA (Tables)	9 Months Ended
	Sep. 30, 2020
Segment Reporting [Abstract]
Schedule of revenues within geographic areas	Three Months Ended Nine Months Ended 2020 2019 2020 2019 Revenues based on customer’s location: Israel $ — $ — $ — $ 2 United States 325 569 1,172 1,492 Europe 413 665 1,990 2,162 Asia-Pacific 2 — 6 36 Latin America 6 — 6 — Africa 1 — 1 — Total revenues $ 747 $ 1,234 $ 3,175 $ 3,692
Schedule of long-lived assets by geographic region	September 30, December 31, 2020 2019 Long-lived assets by geographic region (*): Israel $ 155 $ 179 United States 263 244 Germany 56 78 $ 474 $ 501 (*) Long-lived assets are comprised of property and equipment, net.
Schedule of major customer data as a percentage of total revenues	Nine Months Ended 2020 2019 Major customer data as a percentage of total revenues: Customer A

GENERAL (Details)

GENERAL (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
General (Textual)
Accumulated deficit	$ 178,500		$ 168,469
Negative cash flow from operations	$ 10,131	$ 11,225

SIGNIFICANT ACCOUNTING POLICI_4

SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Total Revenues	$ 747	$ 1,234	$ 3,175	$ 3,692
Units placed [Member]
Total Revenues	522	1,104	2,583	3,350
Spare parts and warranties [Member]
Total Revenues	$ 225	$ 130	$ 592	$ 342

SIGNIFICANT ACCOUNTING POLICI_5

SIGNIFICANT ACCOUNTING POLICIES (Details 1) - USD ($) $ in Thousands		Sep. 30, 2020	Dec. 31, 2019
Accounting Policies [Abstract]
Trade receivable, net	[1]	$ 715	$ 794
Deferred revenues	[1],[2]	$ 1,071	$ 844
[1]	Balance presented net of unrecognized revenues that were not yet collected.
[2]	$345 thousand of December 31, 2019 deferred revenues balance were recognized as revenues during the nine months ended September 30, 2020.

SIGNIFICANT ACCOUNTING POLICI_6

SIGNIFICANT ACCOUNTING POLICIES (Details 2)	9 Months Ended		12 Months Ended
	Sep. 30, 2020		Dec. 31, 2019
Customer A [Member]
Concentration of credit risk	15.00%			[1]
Customer B [Member]
Concentration of credit risk	13.00%			[1]
Customer C [Member]
Concentration of credit risk	13.00%			[1]
Customer D [Member]
Concentration of credit risk	13.00%			[1]
Customer E [Member]
Concentration of credit risk	12.00%			[1]
Customer F [Member]
Concentration of credit risk	11.00%		12.00%
Customer G [Member]
Concentration of credit risk		[1]	14.00%
Customer H [Member]
Concentration of credit risk		[1]	13.00%
Customer I [Member]
Concentration of credit risk		[1]	13.00%
Customer J [Member]
Concentration of credit risk		[1]	12.00%
Customer K [Member]
Concentration of credit risk		[1]	12.00%
Customer L [Member]
Concentration of credit risk		[1]	12.00%
[1]	Less than 10%

SIGNIFICANT ACCOUNTING POLICI_7

SIGNIFICANT ACCOUNTING POLICIES (Details 3) $ in Thousands	9 Months Ended
	Sep. 30, 2020USD ($)
Warranty provision:
Balance at December 31, 2019	$ 277
Provision	60
Usage	(133)
Balance at September 30, 2020	$ 154

SIGNIFICANT ACCOUNTING POLICI_8

SIGNIFICANT ACCOUNTING POLICIES (Details Textual) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2020	Dec. 31, 2019
Significant Accounting Policies (Textual)
Allowance for doubtful accounts	$ 31	$ 31
Net of sales return reserve	0	$ 86
Deferred revenues recognized	$ 345
Performance obligation, description	The Company’s unfilled performance obligations as of September 30, 2020 and the estimated revenue expected to be recognized in the future related to the service type warranty amounts to $1,088 thousand, which is fulfilled over one to five years.
ReStore product [Member]
Significant Accounting Policies (Textual)
Service policy	2 years
MediTouch product [Member]
Significant Accounting Policies (Textual)
Service policy	1 year
Myolyn product [Member] | Minimum [Member]
Significant Accounting Policies (Textual)
Service policy	3 years
Myolyn product [Member] | Maximum [Member]
Significant Accounting Policies (Textual)
Service policy	10 years

INVENTORIES (Details)

INVENTORIES (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Inventory Disclosure [Abstract]
Finished products	$ 2,954	$ 2,394
Raw materials	753	729
Inventories	$ 3,707	$ 3,123

COMMITMENTS AND CONTINGENT LI_3

COMMITMENTS AND CONTINGENT LIABILITIES (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
2020	$ 167
2021	668
2022	637
2023	461
Total lease payments	1,933
Less: imputed interest	(326)
Present value of future lease payments	1,607
Less: current maturities of operating leases	(622)	$ (637)
Non-current operating leases	$ 985	$ 1,315
Weighted-average remaining lease term (in years)	2 years 11 months 4 days
Weighted-average discount rate	12.60%

COMMITMENTS AND CONTINGENT LI_4

COMMITMENTS AND CONTINGENT LIABILITIES (Details Textual) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Commitments and Contingent Liabilities (Textual)
Non-cancelable outstanding obligations	$ 900		$ 900
Maximum penalties payable on early release of agreement	23		23
Royalties expenses	2	$ 8	$ 5	$ 13
Lease expiration, term			These leases expire between 2020 and 2023.
Other long-term assets	686		$ 686
Lease expense	178	$ 185	$ 553	$ 560
RRL and RRG [Member]
Commitments and Contingent Liabilities (Textual)
Lease expiration, term			RRL and RRG lease cars for their employees under cancelable operating lease agreements expiring at various dates in between 2020 and 2023.
IIA [Member]
Commitments and Contingent Liabilities (Textual)
Total fund received			$ 1,970
Royalty bearing grants			1,570
Royalties paid			$ 92
Percentage of obligation to pay royalties			3.00%
Contingent liability	$ 1,600		$ 1,600
Percentage of grant received			100.00%
IIA [Member] | Convertible preferred A shares [Member]
Commitments and Contingent Liabilities (Textual)
Amount received in consideration of preferred shares			$ 400
Convertible preferred shares	209		209
IIA and BIRD [Member]
Commitments and Contingent Liabilities (Textual)
Total fund received			$ 500
Kreos Capital V [Member]
Commitments and Contingent Liabilities (Textual)
Line of credit	$ 20,000		$ 20,000
IPO [Member]
Commitments and Contingent Liabilities (Textual)
Description of conversion ratio			Ordinary shares in a conversion ratio of 1 to 1.

PAYCHECK PROTECTION PROGRAM L_3

PAYCHECK PROTECTION PROGRAM LOAN (Details) $ in Thousands	Sep. 30, 2020USD ($)
Debt Disclosure [Abstract]
Remainder of 2020	$ 43
2021	263
2022	88
Total principal payments	394
Current portion	240
Long-term portion	154
Note payable, net	$ 394

PAYCHECK PROTECTION PROGRAM L_4

PAYCHECK PROTECTION PROGRAM LOAN (Details Textual) - Paycheck Protection Program Loan [Member] - Silicon Valley Bank [Member] $ in Thousands	1 Months Ended
	Apr. 21, 2020USD ($)
Debt Instrument [Line Items]
Unsecured promissory note	$ 392
Interest rate	1.00%
Initial period of loan	2 years

RESEARCH COLLABORATION AGREEM_2

RESEARCH COLLABORATION AGREEMENT AND LICENSE AGREEMENT (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		9 Months Ended
	Apr. 30, 2018	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Research Collaboration Agreement and License Agreement (Textual)
Research and development expenses		$ 756	$ 1,018	$ 2,695	$ 4,292
Harvard License Agreement and Collaboration Agreement [Member]
Research Collaboration Agreement and License Agreement (Textual)
Total payment obligation				7,200
Research and development expenses		$ 175		$ 599
Research collaboration agreement expire date	May 16, 2022			Feb. 28, 2023

SHAREHOLDERS' EQUITY (Details)

SHAREHOLDERS' EQUITY (Details)	9 Months Ended
	Sep. 30, 2019$ / shares
Share-based Payment Arrangement [Abstract]
Expected volatility	57.50%
Risk-free rate	2.22%
Dividend yield
Expected term (in years)	6 years 1 month 9 days
Share price	$ 5.37

SHAREHOLDERS' EQUITY (Details 1

SHAREHOLDERS' EQUITY (Details 1) - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2020	Dec. 31, 2019
Share-based Payment Arrangement [Abstract]
Number, Options outstanding at the beginning of the period	74,713
Number, Granted		12,425
Number, Exercised
Number, Forfeited	(1,713)
Number, Options outstanding at the end of the period	73,000	74,713
Number, Options exercisable at the end of the period	53,668
Average exercise price, Options outstanding at the beginning of the period	$ 41.6
Average exercise price, Granted
Average exercise price, Exercised
Average exercise price, Forfeited	133.74
Average exercise price, Options outstanding at the end of the period	39.4	$ 41.6
Average exercise price, Options exercisable at the end of the period	$ 46.39
Average remaining contractual life (in years), Options outstanding at the beginning of the period	5 years 6 months 25 days	6 years 4 months 2 days
Average remaining contractual life (in years), Options exercisable at the end of the period	4 years 8 months 26 days
Aggregate intrinsic value (in thousands), Options outstanding		$ 135
Aggregate intrinsic value (in thousands), Options exercisable at the end of the period

SHAREHOLDERS' EQUITY (Details 2

SHAREHOLDERS' EQUITY (Details 2) - Employee Stock Option And Restricted Stock Units Rsu [Member]	9 Months Ended
	Sep. 30, 2020$ / sharesshares
Number of shares underlying outstanding RSUs
Unvested RSUs at the Beginning of the period | shares	62,378
Granted | shares	1,238,688
Vested | shares	(44,625)
Forfeited | shares	(9,126)
Unvested RSUs at the end of the period | shares	1,247,315
Weighted average grant date fair value
Unvested RSUs at the Beginning of the period | $ / shares	$ 44.61
Granted | $ / shares	0.85
Vested | $ / shares	8.86
Forfeited | $ / shares	8.46
Unvested RSUs at the end of the period | $ / shares	$ 2.78

SHAREHOLDERS' EQUITY (Details 3

SHAREHOLDERS' EQUITY (Details 3) - Employee Stock Option [Member]	9 Months Ended
	Sep. 30, 2020$ / sharesshares
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options outstanding	1,320,315
Options outstanding weighted average remaining contractual life (years)	5 years 6 months 25 days	[1]
Options outstanding and exercisable	53,668
Options exercisable weighted average remaining contractual life (years)	4 years 8 months 26 days	[1]
5.37 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price | $ / shares	$ 5.37
Options outstanding	12,425
Options outstanding weighted average remaining contractual life (years)	8 years 5 months 27 days	[1]
Options outstanding and exercisable	4,659
Options exercisable weighted average remaining contractual life (years)	8 years 5 months 27 days	[1]
20.42 - 33.75 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price, minimum | $ / shares	$ 20.42
Range of exercise price, maximum | $ / shares	$ 33.75
Options outstanding	36,299
Options outstanding weighted average remaining contractual life (years)	5 years 6 months 3 days	[1]
Options outstanding and exercisable	26,120
Options exercisable weighted average remaining contractual life (years)	4 years 8 months 12 days	[1]
37.14 - 38.75 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price, minimum | $ / shares	$ 37.14
Range of exercise price, maximum | $ / shares	$ 38.75
Options outstanding	10,092
Options outstanding weighted average remaining contractual life (years)	3 years 2 months 16 days	[1]
Options outstanding and exercisable	10,092
Options exercisable weighted average remaining contractual life (years)	3 years 2 months 16 days	[1]
50 - 52.5 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price, minimum | $ / shares	$ 50
Range of exercise price, maximum | $ / shares	$ 52.5
Options outstanding	11,228
Options outstanding weighted average remaining contractual life (years)	4 years 10 months 28 days	[1]
Options outstanding and exercisable	9,841
Options exercisable weighted average remaining contractual life (years)	4 years 8 months 2 days	[1]
182.5 - 524.25 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of exercise price, minimum | $ / shares	$ 182.5
Range of exercise price, maximum | $ / shares	$ 524.25
Options outstanding	2,956
Options outstanding weighted average remaining contractual life (years)	4 years 7 months 6 days	[1]
Options outstanding and exercisable	2,956
Options exercisable weighted average remaining contractual life (years)	4 years 7 months 6 days	[1]
RSUs only [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
RSUs outstanding	1,247,315
Options outstanding weighted average remaining contractual life (years)	0 years	[1]
Options outstanding and exercisable
Options exercisable weighted average remaining contractual life (years)	0 years	[1]
[1]	Calculation of weighted average remaining contractual term does not include the RSUs that were granted, which have an indefinite contractual term.

SHAREHOLDERS' EQUITY (Details 4

SHAREHOLDERS' EQUITY (Details 4)	9 Months Ended
	Sep. 30, 2020$ / sharesshares
Class of Warrant or Right [Line Items]
Warrants outstanding	10,304,914
Warrants outstanding and exercisable	10,304,914
December 31, 2015 [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	4,771	[1]
Exercise price per warrant | $ / shares	$ 7.500	[1]
Warrants outstanding and exercisable	4,771	[1]
Contractual term	Dec. 30, 2025	[1]
November 1, 2016 [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	97,496	[2]
Exercise price per warrant | $ / shares	$ 118.750	[2]
Warrants outstanding and exercisable	97,496	[2]
Contractual term	Nov. 1, 2021	[2]
December 28, 2016 [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	1,908	[3]
Exercise price per warrant | $ / shares	$ 7.500	[3]
Warrants outstanding and exercisable	1,908	[3]
Contractual term	Dec. 30, 2025	[3]
November 20, 2018 [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	126,839	[4]
Exercise price per warrant | $ / shares	$ 7.500	[4]
Warrants outstanding and exercisable	126,839	[4]
Contractual term	Nov. 20, 2023	[4]
November 20, 2018 One [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	106,680	[5]
Exercise price per warrant | $ / shares	$ 9.375	[5]
Warrants outstanding and exercisable	106,680	[5]
Contractual term	Nov. 15, 2023	[5]
February 25, 2019 [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	45,600	[6]
Exercise price per warrant | $ / shares	$ 7.187	[6]
Warrants outstanding and exercisable	45,600	[6]
Contractual term	Feb. 21, 2024	[6]
April 5, 2019 [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	408,457	[7]
Exercise price per warrant | $ / shares	$ 5.140	[7]
Warrants outstanding and exercisable	408,457	[7]
Contractual term	Oct. 7, 2024	[7]
April 5, 2019 One [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	49,015	[8]
Exercise price per warrant | $ / shares	$ 6.503	[8]
Warrants outstanding and exercisable	49,015	[8]
Contractual term	Apr. 3, 2024	[8]
June 5, 2019 and June 6, 2019 [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	1,464,665	[9]
Exercise price per warrant | $ / shares	$ 7.500	[9]
Warrants outstanding and exercisable	1,464,665	[9]
Contractual term	Jun. 5, 2024	[9]
June 5, 2019 [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	87,880	[10]
Exercise price per warrant | $ / shares	$ 9.375	[10]
Warrants outstanding and exercisable	87,880	[10]
Contractual term	Jun. 5, 2024	[10]
June 12, 2019 [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	416,667	[11]
Exercise price per warrant | $ / shares	$ 6	[11]
Warrants outstanding and exercisable	416,667	[11]
Contractual term	Dec. 12, 2024	[11]
June 10, 2019 [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	50,000	[12]
Exercise price per warrant | $ / shares	$ 7.500	[12]
Warrants outstanding and exercisable	50,000	[12]
Contractual term	Jun. 10, 2024	[12]
February 10, 2020 [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	4,343,500	[13]
Exercise price per warrant | $ / shares	$ 1.250	[13]
Warrants outstanding and exercisable	4,343,500	[13]
Contractual term	Feb. 10, 2025	[13]
February 10, 2020 One [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	336,000	[14]
Exercise price per warrant | $ / shares	$ 1.5625	[14]
Warrants outstanding and exercisable	336,000	[14]
Contractual term	Feb. 10, 2025	[14]
July 6, 2020 [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	2,469,139	[15]
Exercise price per warrant | $ / shares	$ 1.76	[15]
Warrants outstanding and exercisable	2,469,139	[15]
Contractual term	Jul. 2, 2025	[15]
July 6, 2020 One [Member]
Class of Warrant or Right [Line Items]
Warrants outstanding	296,297	[16]
Exercise price per warrant | $ / shares	$ 2.2781	[16]
Warrants outstanding and exercisable	296,297	[16]
Contractual term	Jul. 2, 2025	[16]
[1]	Represents warrants for ordinary shares issuable upon an exercise price of $7.5 per share, which were granted on December 31, 2015 to Kreos Capital V (Expert) Fund Limited, or Kreos, in connection with a loan made by Kreos to us and are currently exercisable (in whole or in part) until the earlier of (i) December 30, 2025 or (ii) immediately prior to the consummation of a merger, consolidation, or reorganization of us with or into, or the sale or license of all or substantially all the assets or shares of us to, any other entity or person, other than a wholly-owned subsidiary of us, excluding any transaction in which our shareholders prior to the transaction will hold more than 50% of the voting and economic rights of the surviving entity after the transaction. None of these warrants had been exercised as of September 30, 2020
[2]	Represents warrants issued as part of our follow-on offering in November 2016. At any time, the board of directors may reduce the exercise price of the warrants to any amount and for any period of time it deems appropriate.
[3]	Represents common warrants that were issued as part of the $8.0 million drawdown under the Loan Agreement which occurred on December 28, 2016. See footnote 1 for exercisability terms.
[4]	Represents common warrants that were issued as part of our follow-on offering in November 2018.
[5]	Represents common warrants that were issued to the underwriters as compensation for their role in our follow-on offering in November 2018.
[6]	Represents warrants that were issued to the exclusive placement agent as compensation for its role in our follow-on offering in February 2019.
[7]	Represents warrants that were issued to certain institutional purchasers in a private placement in our registered direct offering of ordinary shares in April 2019.
[8]	Represents warrants that were issued to the placement agent as compensation for its role in our April 2019 registered direct offering.
[9]	Represents warrants that were issued to certain institutional investors in a warrant exercise agreement on June 5, 2019 and June 6, 2019, respectively.
[10]	Represents warrants that were issued to the placement agent as compensation for its role in our June 2019 warrant exercise agreement and concurrent private placement of warrants.
[11]	Represents warrants that were issued to certain institutional purchasers in a private placement in the Company's registered direct offering of ordinary shares in June 2019.
[12]	Represents warrants that were issued to the placement agent as compensation for its role in our June 2019 registered direct offering and concurrent private placement of warrants.
[13]	Represents warrants that were issued to certain institutional purchasers in a private placement in the Company's best efforts offering of ordinary shares in February 2020.
[14]	Represents warrants that were issued to the placement agent as compensation for its role in the Company's February 2020 best efforts offering.
[15]	Represents warrants that were issued to certain institutional purchasers in a private placement in our registered direct offering of ordinary shares in July 2020.
[16]	Represents warrants that were issued to the placement agent as compensation for its role in the Company's July 2020 registered direct offering.

SHAREHOLDERS' EQUITY (Details 5

SHAREHOLDERS' EQUITY (Details 5) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Non-cash share-based compensation expense	$ 544	$ 869
Cost of revenues [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Non-cash share-based compensation expense	6	9
Research and development, net [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Non-cash share-based compensation expense	105	161
Sales and marketing [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Non-cash share-based compensation expense	113	140
General and administrative [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Non-cash share-based compensation expense	$ 320	$ 559

SHAREHOLDERS' EQUITY (Details T

SHAREHOLDERS' EQUITY (Details Textual) $ / shares in Units, $ in Thousands

Jul. 06, 2020$ / sharesshares

Feb. 10, 2020

Jun. 12, 2019$ / sharesshares

Jun. 06, 2019$ / sharesshares

Jun. 05, 2019$ / sharesshares

Apr. 30, 2019$ / sharesshares

Mar. 27, 2019

Feb. 28, 2019USD ($)$ / sharesshares

Nov. 30, 2018

May 31, 2018

Sep. 30, 2020USD ($)shares

Sep. 30, 2020USD ($)$ / sharesshares

Sep. 30, 2019$ / shares

Dec. 31, 2015$ / shares

Sep. 30, 2020₪ / shares

Jul. 06, 2020₪ / shares

Dec. 31, 2019₪ / sharesshares

Dec. 28, 2016USD ($)

Shareholders' Equity (Textual)

Expected term of shares

6 years 1 month 9 days

Description of underwriting agreement

The Company closed a “best efforts” public offering whereby the Company issued an aggregate of 5,600,000 of common units and pre-funded units at a public offering price of $1.25 per common unit and $1.249 per pre-funded unit. As part of the public offering, the Company entered into a securities purchase agreement with certain institutional purchasers. Each common unit consisted of one ordinary share, par value NIS 0.25 per share, and one common warrant to purchase one ordinary share. Each of the 1,546,828 pre-funded unit consisted of one pre-funded warrant to purchase one ordinary share and one common warrant. Additionally, the Company issued warrants to purchase up to 336,000 ordinary shares, with an exercise price of $1.5625 per share, to representatives of H.C. Wainwright as compensation for its role as the placement agent in the Company’s February 2020 offering.

The Company’s follow-on public offering of 496,040 units, each consisting of one ordinary share and one common warrant to purchase one ordinary share with an exercise price of $7.5 per warrant. Each unit was sold to the public at a price of $7.50 per unit. On November 18, 2018, H.C. Wainwright exercised in full its option to purchase 231,964 ordinary shares for $7.25 per share and/or common warrants to purchase up to an additional 231,964 ordinary shares for $0.25 per warrant.

Reverse share split, description

The Company’s shareholders approved (i) a reverse share split within a range of 1:8 to 1:32, to be effective at the ratio and on a date to be determined by the Board of Directors, and (ii) amendments to the Company’s Articles of Association authorizing an increase in the Company’s authorized share capital (and corresponding authorized number of ordinary shares, proportionally adjusting such number for the reverse share split) by up to NIS 17.5 million. Following the shareholder approval, an authorized committee of the Board of Directors of the Company approved a one-for-twenty-five reverse share split of the Company’s ordinary shares, and the Company filed the Third Amended and Restated Articles of Association of the Company with the Registrar of Companies of the State of Israel to effect the reverse share split and to increase the Company’s authorized share capital after the effect of the reverse share split. The reverse share split became effective on April 1, 2019. Additionally, effective at the same time, the total number of ordinary shares the Company is authorized to issue changed from 250,000,000 shares to 60,000,000 shares, the par value per share of the ordinary shares changed to NIS 0.25 and the authorized share capital of the Company changed from NIS 2,500,000 to NIS 15,000,000. All share and per share data included in these condensed consolidated financial statements, for periods before the three months ended June 30, 2019, give retroactive effect to the reverse stock split.

Description of underwriters warrants to purchase

The Company issued and sold 1,050,372 pre-funded units at a price to the public of $7.25 per unit. Each unit containing one pre-funded warrant with an exercise price of $0.25 per share and one warrant to purchase one ordinary share with an exercise price of $7.50 per warrant. The total gross proceeds received from the November 2018 follow-on public offering, before deducting commissions, discounts and expenses, were $13.1 million (including proceeds from the exercise of 90,691 pre-funded warrants at the closing of the offering). As of December 31, 2018, additional pre-funded warrants to purchase an aggregate 562,466 ordinary shares had been exercised, for additional proceeds of $140,617. During the nine month ended September 30, 2019 additional 288,000 pre-funded warrants and 296,087 warrants to purchase an aggregate 584,087 ordinary shares had been exercised, for additional proceeds of $1.5 million. As compensation for their role in the offering, the Company also issued to the underwriters warrants to purchase up to 106,680 ordinary shares, which became immediately exercisable starting on November 20, 2018 until November 15, 2023 at $9.375 per share.

Warrants to purchase ordinary shares | shares

10,000

1,256,500

Ordinary shares, par value | ₪ / shares

₪ 0.25

₪ 0.25

Securities Purchase Agreements [Member]

Shareholders' Equity (Textual)

Exercise price per share | $ / shares

$ 5.14

Number of warrants issued | shares

416,667

408,457

Warrants exercisable, description

Exercisable from July 6, 2020 until January 6, 2026.

Exercisable from June 12, 2019 until December 12, 2024.

Exercisable from June 5, 2019 or June 6, 2019 until June 5, 2024 or June 6, 2024.

Exercisable from June 5, 2019 or June 6, 2019 until June 5, 2024 or June 6, 2024.

Exercisable from April 5, 2019 until October 7, 2024.

Issuance of ordinary shares, shares | shares

833,334

1,464,665

1,464,665

816,914

Exercise price ordinary shares | $ / shares

$ 1.76

$ 6

$ 7.50

$ 7.50

$ 5.2025

Warrants to purchase ordinary shares | shares

2,469,139

Securities Purchase Agreements [Member] | NIS [Member]

Shareholders' Equity (Textual)

Exercise price ordinary shares | $ / shares

$ 0.25

Securities Purchase Agreements [Member] | Additional Warrant to Purchase [Member]

Shareholders' Equity (Textual)

Warrants exercisable, description

Exercisable from July 6, 2020 until July 2, 2025.

Exercisable from June 12, 2019 until June 10, 2024.

Exercisable from June 5, 2019 until June 5, 2024.

Exercisable from June 5, 2019 until June 5, 2024.

Exercisable from April 5, 2019 until April 3, 2024.

Issuance of ordinary shares, shares | shares

50,000

87,880

87,880

49,015

Exercise price ordinary shares | $ / shares

$ 2.2781

$ 7.50

$ 9.375

$ 9.375

$ 6.503125

Warrants to purchase ordinary shares | shares

296,297

Placement agent agreement [Member]

Shareholders' Equity (Textual)

Issuance of ordinary shares (in shares) | shares | shares

760,000

Sale of stock price per share | $ / shares

$ 5.75

Total gross proceeds received from the follow-on public offering | $

$ 4,370

Description of wainwright or its designees warrants to purchase

The Company also issued to H.C Wainwright and/or its designees warrants to purchase up to 45,600 ordinary shares, which are immediately exercisable starting on February 25, 2019 until February 21, 2024 at $7.1875 per share.

Kreos Capital V [Member]

Shareholders' Equity (Textual)

Warrants grant date

Dec. 31, 2015

Warrants exercisable, description

currently exercisable (in whole or in part) until the earlier of (i) December 30, 2025 or (ii) immediately prior to the consummation of a merger, consolidation, or reorganization of us with or into, or the sale or license of all or substantially all the assets or shares of us to, any other entity or person, other than a wholly-owned subsidiary of us, excluding any transaction in which our shareholders prior to the transaction will hold more than 50% of the voting and economic rights of the surviving entity after the transaction.

Kreos Capital [Member]

Shareholders' Equity (Textual)

Exercise price per share | $ / shares

$ 7.5

Drawdown amount under loan agreement | $

$ 8,000

Certain Institutional Investors [Member] | Securities Purchase Agreements [Member]

Shareholders' Equity (Textual)

Issuance of ordinary shares, shares | shares

4,938,278

Ordinary shares, par value | $ / shares

$ 1.8225

Certain Institutional Investors [Member] | Securities Purchase Agreements [Member] | Israel New Shekels [Member]

Shareholders' Equity (Textual)

Ordinary shares, par value | ₪ / shares

₪ 0.25

Timwell Corporation Limited [Member]

Shareholders' Equity (Textual)

Description of tranche consisting

The Company entered into a fee and release agreement with Canaccord Genuity LLC (“Canaccord Genuity”) requiring the Company to pay to Canaccord Genuity, in connection with a settlement, in addition to certain cash amounts, (i) $125 thousand in ordinary shares of the Company after the closing of the first tranche on May 15, 2018 (the “First Tranche Closing”) of the Timwell transaction and (ii) $225 thousand in ordinary shares of the Company after the closing of the Second Tranche of the Timwell transaction (or such lower amount if the Second Tranche Closing is less than $10.0 million). The price per share used for calculation of the number of ordinary shares issued by the Company to Canaccord Genuity is based on the volume weighted average price of the Company’s ordinary shares as reported on the Nasdaq Capital Market for the five consecutive trading days prior to the date of issuance. The Company is also obligated to pay $100 thousand in cash following the closing of the Third Tranche of $5.0 million (or such lower amount if the Third Tranche Closing is less than $5.0 million). Following the First Tranche Closing, the Company issued 4,715 ordinary shares to Canaccord Genuity.

Employee Stock Option [Member]

Shareholders' Equity (Textual)

Award vesting period, description

Options to purchase ordinary shares generally vest over four years, with certain options to non-employee directors vesting quarterly over one year.

Shares reserved for future issuance (in shares) | shares

623,408

623,408

12,409

Unrecognized cost of shares | $

$ 2,000

$ 2,000

Expected term of shares

3 years 2 months 19 days

Restricted Stock Units (RSUs) [Member]

Shareholders' Equity (Textual)

Weighted average grant date fair value, restricted stock units (in USD per share) | $ / shares

$ 1.44

$ 4.69

Weighted average grant date fair value, options (in USD per share) | $ / shares

$ 2.98

FINANCIAL EXPENSES, NET (Detail

FINANCIAL EXPENSES, NET (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Other Income and Expenses [Abstract]
Foreign currency transactions and other	$ (7)	$ (10)	$ (99)	$ (50)
Financial expenses related to loan agreement with Kreos	243	365	802	1,155
Bank commissions	6	5	20	26
Financial expenses, net	$ 242	$ 360	$ 723	$ 1,131

GEOGRAPHIC INFORMATION AND MA_3

GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Revenue, Major Customer [Line Items]
Total revenues	$ 747	$ 1,234	$ 3,175	$ 3,692
Israel [Mmeber]
Revenue, Major Customer [Line Items]
Total revenues				2
United States [Member]
Revenue, Major Customer [Line Items]
Total revenues	325	569	1,172	1,492
Europe [Member]
Revenue, Major Customer [Line Items]
Total revenues	413	665	1,990	2,162
Asia Pacific [Member]
Revenue, Major Customer [Line Items]
Total revenues	2		6	36
Latin America [Member]
Revenue, Major Customer [Line Items]
Total revenues	6		6
Africa [Member]
Revenue, Major Customer [Line Items]
Total revenues	$ 1		$ 1

GEOGRAPHIC INFORMATION AND MA_4

GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA (Details 1) - USD ($) $ in Thousands		Sep. 30, 2020	Dec. 31, 2019
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	[1]	$ 474	$ 501
Israel [Mmeber]
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	[1]	155	179
United States [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	[1]	263	244
Germany [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	[1]	$ 56	$ 78
[1]	Long-lived assets are comprised of property and equipment, net.

GEOGRAPHIC INFORMATION AND MA_5

GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA (Details 2)	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Customer A [Member] | Sales Revenue, Net [Member]
Revenue, Major Customer [Line Items]
Concentration risk		13.13%

GEOGRAPHIC INFORMATION AND MA_6

GEOGRAPHIC INFORMATION AND MAJOR CUSTOMER AND PRODUCT DATA (Details Textual)	9 Months Ended
	Sep. 30, 2020segment
Geographic Information and Major Customer and Product Data (Textual)
Number of reportable segments	1